Investigation of phosphorylation and ligand binding of the focal adhesion targeting domain of focal adhesion kinase by Cable, Jennifer L.
Investigation of Phosphorylation and Ligand Binding of the Focal Adhesion Targeting 
Domain of Focal Adhesion Kinase 
 
 
 
 
Jennifer Lynn Cable 
 
 
 
 
A dissertation submitted to the faculty of the University of North Carolina at Chapel Hill 
in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the 
Department of Biochemistry and Biophysics. 
 
 
 
 
Chapel Hill 
2011 
 
 
 
 
 
 
 
 
 
 
Approved by: 
 
Dr. Sharon Campbell 
 
Dr. Andrew Lee 
 
Dr. Gary Pielak 
 
Dr. Michael Schaller 
 
Dr. Richard Wolfenden
   
 
 
ii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2011 
Jennifer Lynn Cable 
ALL RIGHTS RESERVED 
 
   
 
 
iii 
 
 
 
 
 
 
ABSTRACT 
 
JENNIFER CABLE: Investigation of Phosphorylation and Ligand Binding of the Focal 
Adhesion Targeting Domain of Focal Adhesion Kinase 
(Under the direction of Dr. Sharon Campbell) 
 
 Focal adhesion kinase (FAK) is a nonreceptor tyrosine kinase that localizes to 
focal adhesions upon integrin activation.  FAK plays a key role in cell migration, cell 
cycle progression, and apoptosis.  Because of its role in these processes, it is not 
surprising that FAK is also involved in tumor progression and metastasis.  
Overexpression of FAK often correlates with increased metastasis.  The C-terminal focal 
adhesion targeting (FAT) domain of FAK is required for proper localization and 
subsequent activation of FAK.  Phosphorylation of the FAT domain at Y926 by Src 
kinase is believed to delocalize FAK from focal adhesions and promote cell migration, 
angiogenesis, and tumor metastasis.  Because of its role in such important processes, 
phosphorylation at Y926 is likely to be tightly regulated.  Because the inherent 
conformation of Y926 is not favorable for Src recognition, phosphorylation of Y926 is 
thought to be regulated by changes in the conformation or dynamics of the region 
surrounding Y926.  However, what regulates these conformational changes is unknown.  
In this study, we provide evidence that Src-mediated phosphorylation of Y926 is 
sensitive to pH in vitro and reveal a second site of Src-mediated phosphorylation in the 
FAT domain: Y1008.  NMR studies of the FAT domain reveal pH-dependent changes in 
backbone dynamics in regions shown to be important for phosphorylation.  
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 In addition to understanding how phosphorylation is regulated, we also were 
interested in investigating how phosphorylation itself affects the characteristics of the 
FAT domain.  To address this issue, we characterized several Y926 mutants of the FAT 
domain and determined that perturbation of Y926 affects paxillin binding.  Therefore, it 
is likely that phosphorylation is incompatible with paxillin binding, which supports the 
hypothesis that phosphorylation delocalizes FAK from focal adhesions.    
 Finally, we have investigated a possible interaction between the FAT domain and 
the protein talin.  This interaction has been proposed as a secondary mechanism by which 
the FAT domain localizes FAK to focal adhesions.  However, we were unable to detect 
an interaction under our conditions.   
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CHAPTER 1 
INTRODUCTION 
Focal Adhesions and Cell Migration 
 Cell migration plays a key role in many important cellular processes such as 
wound healing, embryonic development, and immune response.  When left unchecked, 
however, cell migration can lead to tumor invasion and metastasis [2].  Therefore, 
understanding the mechanisms involved in and the regulation of cell migration will prove 
invaluable in finding treatments 
for cancer.  
 Cells migrate via the 
assembly and disassembly of 
integrin-linked sites of attachment 
to the extracellular matrix (ECM), 
known as focal adhesions [3].  
Focal adhesions are formed when 
integrins, a type of 
transmembrane receptor, attach to 
ECM proteins.  This attachment 
causes integrin clustering and 
activation, which recruits several proteins such as paxillin, vinculin, talin, α-actinin, and 
Figure 1.1:  Composition of Focal Adhesions 
Focal adhesions are formed when integrins engage with the 
ECM and cluster, causing the recruitment of a variety of 
proteins which link the ECM to the actin cytoskeleton.  
Extracellular Matrix 
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focal adhesion kinase (FAK) to focal adhesions. As shown in Figure 1.1, this complex of 
proteins links the extracellular matrix to the actin cytoskeleton [4].  The focus of this 
research is on FAK because it is an important component of focal adhesion organization 
and signaling pathways involved in cell migration, adhesion, and proliferation.   
Biological Role of FAK 
 FAK was discovered in 1992 as a highly tyrosine-phosphorylated protein tyrosine 
kinase that localizes to focal adhesions [5, 6].  FAK is expressed in most tissues [6] and is 
highly conserved across species.  Knock-out of FAK in mice results in embryonic 
lethality with defects that resemble those of fibronectin deficiency [7].  FAK-null cells 
display a more rounded phenotype than wild type cells and impaired migration.  Because 
FAK-null cells exhibit a greater number of focal adhesions than wild type cells, the 
defect in cell migration in these cells has been attributed to a loss of focal adhesion 
turnover rather than a defect in focal adhesion formation [7, 8].  Furthermore, disruption 
of FAK by siRNA or anti-FAK antibodies induces apoptosis in both fibroblasts and 
tumor cells [9-12].  While inhibition of FAK leads to decreased migration and increased 
apoptosis, overexpression of FAK leads to an increase in cell migration in Chinese 
hamster ovarian (CHO) cells [13] and carcinoma cells [14] and increased angiogenesis in 
endothelial cells [15].  Therefore, there is strong evidence for a positive role for FAK in 
cell migration and cell survival. 
FAK and Cancer 
 Due to its role in cell migration, cell cycle progression, and apoptosis, it is not 
surprising that several lines of evidence have linked FAK to cancer.  FAK is 
overexpressed in several types of cancer including thyroid, prostate, cervix, colon, 
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rectum, oral epithelium, and ovarian [2, 16], and increased FAK levels are often 
associated with malignancy and metastasis [16, 17].  While FAK has been implicated in 
various processes necessary for metastasis and invasion, its precise role in malignancy is 
unclear.  First, FAK has been implicated in the release of matrix metallo-proteinases, 
which degrade the basement membrane allowing cells to enter the bloodstream and 
invade other tissues [18].  Furthermore, FAK is linked to the release of vascular 
endothelial growth factor (VEGF), which controls the growth of new blood vessels 
necessary for growing tumors [19].   
 Because of the importance of FAK in cell migration and its connection to 
invasive, metastatic cancer, inhibition of FAK has become an attractive strategy for 
treating cancer.  Many current cancer treatments are proapoptotic therapies; however, 
migrating and metastatic cells are generally resistant to apoptosis.  Therefore, there is a 
need for the development of new, anti-migratory treatments to combat and delay 
metastasis of primary tumors [20].  Inhibition of FAK expression by antisense RNA 
reduces cell migration and invasion and increases cell death in carcinoma and melanoma 
cells [21, 22].  Furthermore, inhibition of FAK by siRNA in lung cancer cells decreased 
migration and the ability to grow in soft agar [23].  These data suggest that FAK could be 
a therapeutic target for treating cancer.  Towards that goal, several small molecule 
inhibitors of FAK have been developed.  Most of these compounds are ATP-competitive 
inhibitors, which are notoriously nonselective, although studies are underway to generate 
more selective FAK inhibitors based on allosteric inhibition [24].   
 Several phase I clinical trials investigating FAK inhibitors have either been 
completed or are underway (http://clinicaltrials.gov).  Many of these results are not yet 
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public, but of the results that are available, FAK inhibitors seem to be well tolerated.  
Furthermore, the tyrosine kinase inhibitors dasatinib and bosutinib, which were 
developed to target the Bcr/Abl kinase and have been approved for the treatment of 
chronic myeloid leukemia, have been shown to bind to and inhibit FAK [25].  Also, the 
drug bortezomib, a potent proteasome inhibitor that has been approved for the treatment 
of multiple myeloma, suppresses FAK expression [26, 27]. 
 The development of FAK kinase inhibitors for the use as cancer therapies is still 
in its infancy.  As mentioned above, it is often difficult to design an inhibitor that is 
specific for one kinase.  Such non-specificity can lead to off-target effects and potentially 
unwanted side effects.  Therefore, it is of interest to understand the molecular 
mechanisms of FAK regulation, activation, and activity to determine if there are other 
properties of FAK that can be targeted during drug development, such as disruption of 
protein/protein interactions or selectively targeting a specific conformation of FAK.  
Such strategies could potentially target specific functions of FAK that lead to metastasis 
and invasion while leaving other functions unaffected.  Therefore, it is important to 
understand the structure of FAK and to elucidate how it is regulated either via 
posttranslational modifications or interactions with other proteins. 
Focal Adhesion Kinase 
 FAK is a nonreceptor tyrosine kinase involved in the assembly and disassembly 
of focal adhesions [28].  In addition to its kinase activity, it also functions as a scaffolding 
protein.  Figure 2 shows the domain structure of FAK.  FAK consists of an N-terminal 
FERM (protein 4.1, ezrin, radixin, and moesin homology) domain, a central kinase 
domain, and a C-terminal focal adhesion targeting (FAT) domain.  FAK is recruited to 
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newly forming focal adhesions upon integrin activation.  Interaction of the FERM 
domain of FAK with integrin tails releases autoinhibitory interactions between the FERM 
and kinase domains allowing the FERM domain to interact with other protein tyrosine 
kinases and with actin-associated proteins such as ezrin (See Figure 2) [28-32].  The 
kinase domain is activated by autophosphorylation at Y397, which creates a Src-
homology (SH) 2 binding site that is recognized by, among other proteins, Src kinase.   
After binding to Y397, Src phosphorylates FAK at Y576 and Y577 in the kinase domain, 
which is necessary for complete kinase activity, and at Y926 in the FAT domain [28, 33].  
The FAT domain is responsible for localization of FAK to focal adhesions at least 
partially through its interaction with the protein paxillin [34].  Phosphorylation at Y926 in 
the FAT domain creates an SH2 binding site for the growth factor receptor bound protein 
2 (Grb2) [28], which is believed to occlude FAK from focal adhesions and link it to the 
mitogen-activated 
protein kinase (MAPK) 
pathway, which is 
involved in cell 
proliferation and 
survival [35, 36].  This 
research focuses on the 
FAT domain of FAK as 
it is essential for proper 
FAK localization and 
function and plays a 
Figure 1.2: Domain Structure of FAK   
The FERM domain, kinase domain, and FAT domain are indicated.  
Proteins that bind to a particular domain are indicated below the domain.  
Key sites of tyrosine phosphorylation are also shown.  Proteins with SH2 
domains that bind to the phosphorylated tyrosine residues are shown 
above the residue. 
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key role in FAK-mediated signaling pathways. 
The FAT Domain: Targeting FAK to Focal Adhesions 
 The C-terminal FAT domain of FAK is necessary for proper localization of FAK 
to focal adhesions, which is essential for proper activation and function.  Specifically, 
deletion mutants of FAK that do not contain the C-terminal domain of FAK do not 
localize to focal adhesions [37], suggesting that the FAT domain is necessary for proper 
localization.  Furthermore, FAK-related nonkinase (FRNK), an autonomously expressed 
spliced variant of FAK, which contains the C-terminal domain of FAK, and chimeric 
proteins containing the FAT domain localize to focal adhesions, suggesting that the C-
terminal domain of FAK is also sufficient for localization of FAK [37, 38].    
 While it seems that there are several mechanisms by which the FAT domain can 
direct proper localization of FAK, the major mechanism seems to be the interaction of the 
FAT domain with paxillin.  The FAT domain is necessary for the interaction between 
FAK and paxillin, and mutations in the FAT domain of FAK that impair paxillin binding 
do not localize to focal adhesions whereas FAK constructs that can bind to paxillin do 
localize to focal adhesions [34].     
 Paxillin binds to the FAT domain via its LD motifs, named because of the 
presence of several leucine residues and a key aspartate residue (consensus sequence: 
LDXLLXXL).  Paxillin contains five LD motifs in its N-terminus (LD 1-5), and LD2 and 
LD4 have been shown to bind the FAT domain.  Furthermore, there are two paxillin-
binding sites on the FAT domain, termed the 1,4 and 2,3 sites, described in more detail 
below.  While structures of FAT bound to paxillin peptides have been solved, it is unclear 
how the proteins interact in a larger context, i.e., whether paxillin binds to two FAK 
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molecules via its LD2 and LD4 motifs or whether the LD2 and LD4 motifs of one 
paxillin molecule bind simultaneously to one FAK molecule.  However, it has been 
shown that the LD2 and LD4 motifs can simultaneously bind to one FAT molecule in 
vitro and that the 2,3 site in the FAT domain can bind to both LD2 and LD4 whereas the 
1,4 site has a stronger preference for LD2 [39, 40].  A model has been proposed in which 
the LD2 motif binds to the 1,4 site in the FAT domain, paxillin wraps around helices-3 
and -4, and the LD4 motif binds to the 2,3 site [40].   
 While both paxillin binding sites in the FAT domain are necessary for maximal 
activity of FAK, only one site is required to target FAK to focal adhesions [39].  
However, it appears that the two paxillin binding sites are not completely redundant as 
mutation of the 1,4 site has a more drastic effect on FAK localization than mutation of 
the 2,3 site, suggesting that the 1,4 site is more important for proper localization of FAK.  
Interestingly, FAK is still able to localize to focal adhesions upon mutation of both 
paxillin binding sites, albeit to a lesser extent (~10% of wild type), suggesting that there 
is a secondary mechanism for FAK localization that is independent of its interaction with 
paxillin [39].   
 One possibility for this paxillin-independent mechanism of localization is the 
interaction of the FAT domain with talin.  Talin co-immunoprecipitates with FAK, 
suggesting an interaction in vivo [41, 42], and deletion of residues 965-1012 of FAK, 
which are in the FAT domain, abrogates binding to talin, suggesting that talin binds to the 
FAT domain of FAK [41].  Interestingly, Pyk2, a close homolog of FAK that does not 
localize to focal adhesions does not bind to talin.  However, a chimeric protein containing 
the N-terminal domains of Pyk2 and the C-terminal domain of FAK is able to bind talin 
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and localize to focal adhesions [42].  These data suggest that talin binding to the FAT 
domain of FAK may be involved in localization to focal adhesions.  However, more 
recent studies have had difficulties detecting an interaction between FAK and talin [39], 
and the role for a FAK/talin interaction remains elusive and controversial.  
Phosphorylation of Y926 
 In addition to its role in localization, the FAT domain also plays an important role 
in FAK signaling via Src-mediated phosphorylation of Y926.  Phosphorylation of Y926 
has been linked to delocalization of FAK from focal adhesions and focal adhesion 
turnover due to reports that phosphorylation of a membrane-anchored construct of FAK 
was shown to exclude FAK from focal adhesions whereas a Y926F variant of FAK 
remained at focal adhesions [28, 35].  While the mechanism by which phosphorylation 
occludes FAK from focal adhesions is unclear, it has been proposed that phosphorylation 
at Y926 disrupts FAK/paxillin interactions leading to delocalization of FAK from focal 
adhesions and subsequent focal adhesion disassembly [34, 43-45].  
 Y926 exists in a canonical Grb2 SH2 domain binding motif (YXNX) [46], and 
phosphorylation at this site creates an SH2 domain binding site for Grb2, linking FAK to 
the MAPK/ERK pathway [33, 36].  Mutation of Y926 to phenylalanine suppresses ERK 
activation, which leads to a decrease in VEGF expression and tumor growth and 
vascularization in breast carcinoma cells [19] as well as decreased metastasis and 
invasion in melanoma cells [47].  These studies suggest that phosphorylation of Y926 is 
intimately involved in FAK’s role in cancer progression and metastasis and that targeting 
this site could represent a potential strategy in designing cancer therapeutics.    
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Structure and Dynamics of the FAT Domain  
 Because of the importance of the FAT domain in FAK localization and signaling, 
understanding the mechanisms by which the FAT domain is regulated at the molecular 
level will provide insight into FAK’s role in cancer.  Both solution state and crystal 
structures of the FAT domain, shown in Figure 1.3, indicate that it forms an anti-parallel 
four-helix bundle [44, 48, 49].  However, the crystal structure of a domain swapped 
dimer (Fig. 1.3D), in which helix-1 partitions away from the four helix bundle and packs 
against the other three helices of a second FAT molecule, has also been reported [48].  
The observation of the domain-swapped dimer caused the authors to speculate that the 
mechanism involved in forming the dimer, i.e., the opening of helix-1, would result in 
exposure of Y926, rendering this residue more accessible for phosphorylation by Src and 
for binding to Grb2.   
 While it is unclear whether the domain-swapped dimer represents a biologically-
relevant species, there is evidence that helix-1 has a propensity to partition from the four-
helix bundle in solution.  NMR studies of the FAT domain indicate that residues in the 
Figure 1.3: Structure of the FAT Domain 
Both NMR (A) and crystal (B,C) structures of the FAT domain indicate that it is a four-helix 
bundle.  One crystal structure (D) has been solved in which helix-1 forms a domain-swapped 
dimer with a second molecule.  The site of phosphorylation (Y926) is shown in yellow. 
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loop between helix-1 and helix-2 are broadened at 25°C and become more narrow at 
37°C, indicating that this region is in exchange between two or more conformations on 
the NMR timescale and that helix-1 may be conformationally flexible in solution [49].  
To further investigate the conformational flexibility of helix-1 in the FAT domain, our 
lab used a combination of hydrogen exchange (HEX) and discrete molecular dynamics 
(DMD) to visualize intermediate conformations that may only be weakly populated in 
solution.  Figure 1.4 shows the folding intermediate observed in the DMD simulations in 
which helix-1 partitions from the four-helix bundle [50].  For comparison, the monomer 
from the domain-swapped dimer is also shown.  In both of these species, helix 1 has 
partitioned away from the four-helix bundle.  In addition, a “hidden folding intermediate” 
similar to that detected in the wild type FAT domain [50] has been detected in a Y926E 
mutant of the FAT domain, which was used to mimic the phosphorylated form.  These 
studies included hydrogen exchange experiments as a function of denaturant to detect the 
presence of folding intermediates and stopped-flow fluorescence to investigate the 
kinetics of folding.  The intermediate state was determined to be ~4 kcal/mol more stable 
than the unfolded states and represents ~0.1% of the population [51].  The domain-
swapped dimer, solution structure, and hydrogen exchange and molecular dynamics data 
support the idea that the FAT domain can adopt two conformations: a closed form with 
helix-1 packed in the helix bundle and an open form with helix-1 partitioned away from 
the bundle.   
 The partitioning of helix-1 is likely facilitated by strain caused by a series of 
proline residues (PAPP) in the loop between helices-1 and -2; the partitioning of helix-1 
serves to relieve this strain.  Proline residues are often found in the hinge regions of  
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domain swapped dimers due to their unique characteristics.  First, because the proline 
side chain is covalently bonded to the backbone, it can adopt a limited number of phi/psi 
angles.  Second, because prolines lack an amide hydrogen, it cannot participate in 
hydrogen bonds and is often excluded from normal secondary structural elements.  
Finally, proline is the only amino acid that restricts the conformation of the residue 
preceding it, thus introducing conformational flexibility in two consecutive residues [52]. 
Proline-induced domain swapping has been observed in p13suc1 [53], RNaseA [54], and 
bleomycin resistance protein [52].  Therefore, it seems likely that the series of proline 
residues in helix-1 of the FAT domain could promote the partitioning of helix-1 from the 
four-helix bundle.  We have dubbed the loop between helices-1 and -2 a putative “hinge 
region” and speculated that dynamics in the hinge region may regulate the partitioning of 
helix-1 from the four-helix bundle.   
Functional Consequences of Conformational Dynamics 
If the FAT domain can exist in two distinct conformations (open and closed), the 
question remains whether these two conformations are distinct functionally.  Several 
Figure 1.4: Intermediate of 
the FAT Domain:  
A. Intermediate of the FAT 
domain detected by HEX-directed 
DMD.  In this intermediate, helix 
1 is partitioned away from the 
four-helix bundle.  B. One of the 
monomers from the crystal 
structure of the domain-swapped 
dimer (See Figure 1.3).  In this 
structure as well, helix 1 is 
partitioned away from the four-
helix bundle.   
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structures of the FAT domain bound to peptides mimicking the paxillin LD motifs have 
been solved [43, 55, 56].  Figure 1.5 shows the NMR structure of the FAT domain bound 
to a 28-mer peptide that mimics the LD2 motif of paxillin.  One of the paxillin binding 
sites is in a hydrophobic groove between helices-1 and -4 while the other site is in a 
hydrophobic groove between helices-2 and -3.   
If helix-1 partitions away 
from the bundle to form the 
open conformation, as has been 
suggested based on NMR and 
DMD [50, 51] data as described 
above, this would likely disrupt 
paxillin binding.  Therefore, the 
closed form of the FAT domain 
is likely the form that is 
involved in paxillin binding.  On 
the other hand, the open form of 
the FAT domain would be 
expected to expose Y926.  
Previous studies have indicated 
that Y926 is difficult to 
phosphorylate in vitro [48], suggesting that this residue is not in a conformation that is 
easily recognized by Src kinase.  Indeed, crystal structures of kinases bound to substrate 
peptides indicate that the substrate is in an extended conformation.  For example, crystal 
Figure 1.5: Solution Structure of FAT Bound to LD2 
peptides 
The FAT domain (green) bound to two LD2 peptides (blue, 
spheres) (PDB 1QVX).  LD2 binds to the 1,4 site (left) and 2,3 
site (right) on the FAT domain.  Y926 is shown in red to 
demonstrate how paxillin binding is expected to occlude 
phosphorylation at Y926.      
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structures of the tyrosine kinases insulin receptor tyrosine kinase (IRK), epidermal 
growth factor receptor (EGFR), and Abelson leukemia tyrosine kinase (Abl) bound to 
substrate peptide analogs reveal that the substrate adopts an extended β-strand 
conformation that forms an antiparallel β-strand interaction with the activation loop of 
the kinase [57, 58].  Perhaps more relevant, an NMR structure of the substrate peptide 
immunoreceptor tyrosine-based activation motif (ITAM) bound to Lyn kinase, a Src-
family kinase, reveals that ITAM adopts an irregular helix conformation in which the side 
chains are oriented in the same direction [59].  The site of phosphorylation in the FAT 
domain is in a helix, which, based on the previous structural data mentioned above, is not 
conducive to recognition and phosphorylation by Src kinase.  One hypothesis for how 
Y926 is phosphorylated is that the partitioning of helix-1 causes the helix to become 
disordered and thus a better substrate for Src.  Therefore, based on the structural data 
described above, it appears that when in the closed form, the FAT domain is able to bind 
paxillin and localize to focal adhesions whereas in the open form, the FAT domain is 
more readily phosphorylated at Y926, which results in delocalization from focal 
adhesions.   
 Once the FAT domain is phosphorylated, conformational dynamics are also 
expected to play a role in its function.  Phosphorylation at Y926 creates a binding site for 
the SH2 domain of Grb2; however, this site is not in a conformation that is easily 
recognizable by Grb2.  Structures of peptides bound to Grb2 indicate that the peptide 
exists in a compact, type I β-turn conformation [60-62].  The SH2 domain of Grb2 is 
unique among SH2 domains in that a tryptophan residue in the specificity-determining 
loop closes the binding cleft and forces the substrate to adopt a β-turn conformation in 
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which the pY and the N+2 are near each other.  In addition, difficulties in observing a 
direct interaction between Grb2 and the FAT domain have been reported, and an 
interaction was only observed upon denaturation of the phosphorylated FAT domain, 
suggesting that Y926 is not inherently in a conformation that is conducive to Grb2 
binding [48].  Therefore, while it appears that helix-1 must adopt an extended 
conformation to be phosphorylated by Src, the phosphorylated form must also adopt a 
distinct conformation to bind Grb2.   
 In summary, several lines of evidence suggest that inherent conformational 
dynamics of the FAT domain regulate phosphorylation and ligand binding.  The 
conformation of the FAT domain that is likely to be conducive to phosphorylation and 
Grb2 binding (open form) is a minor species in solution.  Therefore, we postulate that the 
cell has a mechanism that promotes a distinct or open form of the FAT domain to 
facilitate phosphorylation by Src or Grb2 binding.  However, the identity of this 
mechanism remains a mystery.  We postulate that pH may be a mechanism for regulating 
conformational dynamics of the FAT domain, which in turn modulates phosphorylation 
and ligand binding.  To test this hypothesis, we have examined the role of pH on the 
dynamics of the FAT domain and how pH-dependent dynamics affect the stability and 
phosphorylation of the FAT domain. 
pH and Cell Migration 
 Cells must establish a spatial and temporal polarity to achieve directed migration.  
One of the suggested mechanisms by which the cell achieves this is the establishment of 
a pH gradient.  Both extracellular and intracellular pH gradients have been observed in 
migrating cells [63, 64].  Depending on the cell type, the intracellular pH of the leading 
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edge of the cell was found to be more basic than the trailing edge by 0.05 to 0.16 pH 
units [63], and the extracellular pericellular proton concentration increased by a factor of 
two at the leading edge of cells compared to the trailing edge [64].  These gradients are 
achieved by localization of the sodium/proton exchanger 1 (NHE1) to the leading edge of 
migrating cells.  NHE1 regulates intracellular pH by exchanging intracellular protons for 
extracellular sodium ions.  Its ion-transport activity is essential for establishing cell 
polarization, protrusion, and adhesion [65].  Furthermore, NHE1 co-localizes with 
vinculin and talin, common focal adhesion markers [66], and FAK has been implicated in 
regulating proper localization of NHE1 [67].   
 Changes in intracellular pH have been proposed to promote cell proliferation [68], 
to initiate and direct cell migration [65], and to trigger apoptosis [69], though the exact 
role of pH changes in these processes remains controversial [70].  An increase in 
cytosolic pH (0.3-0.5 units) has been shown to promote directed cell migration by 
promoting focal adhesion remodeling through the regulation of actin filament assembly, 
bundling, and cell adhesion [71, 72] and is a hallmark of transformed cells and a common 
characteristic of many different cancers.  In contrast, a decrease in cytosolic pH (0.3-0.4 
units) promotes apoptosis [71].      
The processes by which pH regulates cell migration remain to be fully elucidated.  
However, the activities and interactions of several proteins associated with migration 
have been shown to be pH dependent, and the structural mechanisms for these pH 
dependencies have been investigated.  For example several proteins that localize to actin-
rich structures, such as cofilin, villin, and talin, have been shown to be sensitive to 
changes in pH.  In the case of cofilin, its actin-severing activity increases whereas it 
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ability to bind phophoinositides decreases as the pH increases.  Its sensitivity to pH is 
thought to result from disruption of a salt bridge between His 133 and Asp 98 between 
pH 6.9 and 7.2.  Because NMR data and MD simulations indicate that any pH-dependent 
structural changes are subtle and localized, it is believed that de/protonation of His 133 
directly affects actin binding because this residue lies in the actin binding site [64, 71].  
Another actin-associated protein that is sensitive to pH is villin.  At pH 6.5, CD, NMR, 
and hydrogen-exchange data indicate that the N-terminus of villin is unstructured.  
Raising the pH causes the N-terminus to fold, which stabilizes the C-terminal actin-
binding domain.  It is thought that a positive charge on H41 at low pH destabilizes 
hydrophobic packing, causing the N-terminus to become unstructured.  When the 
histidine is deprotonated, this instability is relieved, and the domain can fold [71].  
Finally, the talin has been shown to bind to actin in a pH-dependent manner.  It has a 
lower affinity for actin at higher pH.  Molecular dynamics and NMR have revealed a 
region of titratable amino acids with upshifted pKa values in a region distal from the actin 
binding site.  It is believed that protonation of H418 in this region changes the 
conformation and dynamics of the actin binding site, thus affecting the binding affinity.  
The pH-dependent talin-actin interaction could play a role in focal adhesion remodeling 
and therefore in cell migration.   
pH and the FAT Domain 
 Due to the role of intracellular pH in cell migration and adhesion and the link 
between NHE1 and focal adhesion proteins, including FAK, it is possible that pH plays a 
role in FAK regulation in vivo.  While it is unclear if pH plays a role in the regulation of 
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the FAT domain in vivo, we have in vitro data that suggest that the structure, dynamics, 
and function of the FAT are sensitive to pH within physiological limits.   
 One of the main differences between the solution structure of the FAT domain 
and current crystal structures is pH.  The solution structure of the FAT domain was 
solved at pH 6.0 while the crystal structures were solved at pH 7.0 for the monomer and 
at pH 6.5 for the domain swapped dimer (See Figure 1.3).  While the solution and crystal 
structures are very similar, there are some differences.  The main structural difference 
between the solution and crystal structures lies in helix-1; there is an extra turn in helix-1 
between helices-1 and -2 in the crystal structure.  Whether this difference is a result of 
crystal packing or of a pH dependent conformational change is unclear.  However, as 
described above, the loop between helix-1 and -2 has been shown to be conformationally 
flexible, and this flexibility has been implicated in regulating phosphorylation of Y926 
[49, 50].  Therefore, if the region between helices-1 and -2 in the FAT domain is 
sensitive to pH, then it is possible that phosphorylation of Y926 could be regulated by 
pH.  Understanding how phosphorylation of Y926 is regulated in vitro could lead to 
insights regarding how this site is regulated in vivo and help elucidate how FAK and 
specifically phosphorylation at Y926 is involved in cell migration and metastasis.  
Conclusion  
 In conclusion, several lines of evidence confirm that conformational dynamics of 
the FAT domain are important for the regulation of FAK function.  While it is currently 
unclear how these dynamics are regulated in the cell, we have characterized pH-
dependent conformational dynamics in vitro and provide evidence that pH-induced 
changes in dynamics promote changes in phosphorylation of the FAT domain.  A second 
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goal of this work is to understand how phosphorylation itself affects the structure and 
dynamics of the FAT domain.  Due to complications arising from a secondary 
phosphorylation site, we could not isolate and characterize conformational and dynamic 
properties of FAT singly phosphorylated at Y926.  However, we have been able to 
characterize how changes via mutation at position 926 affect the stability of the FAT 
domain and its ability to bind paxillin.  Amino acid substitution of asparate or glutamate 
at this position was used to mimic the phosphorylated form of FAT whereas a Y926F 
mutant was employed to determine how a non-phosphorylatable mutant affects FAT 
function in vitro.  We discovered that mutation of Y926 to any of several residues 
disrupts paxillin binding, suggesting that any perturbation at this site, for example 
phosphorylation, is likely to disrupt paxillin binding as well.  Because paxillin binding is 
important for proper localization of FAK, disruption of paxillin binding could lead to 
delocalization of FAK from focal adhesions.  Finally, we have also investigated 
interactions between the FAT domain of FAK and the F3 domain of talin as binding to 
talin has been proposed as a paxillin-independent mechanism for FAK localization.  
  
 
CHAPTER 2 
pH AND THE FAT DOMAIN 
Introduction 
 All proteins depend on pH to maintain their proper structure and function.  It is 
therefore not surprising that the cytosolic pH is tightly regulated by several ion pumps 
that pump protons into and out of the cell.  While the main purpose of these pumps may 
be to maintain pH homeostasis, they also create localized pH gradients and fluctuations, 
which could act as a signal by altering the structure, activity, and interactions of proteins.  
In fact, the activities of several proteins involved in actin-mediated cell migration such as 
cofilin [64, 71], villin [71], and talin [72] are sensitive to pH.  While the biological 
consequences of these proteins’ sensitivity to pH remain to be fully elucidated, changes 
in intracellular pH have been proposed to promote cell proliferation [68], to initiate and 
direct cell migration [65], and to trigger apoptosis [69].  
 pH gradients are proposed to be one of the mechanisms by which cells establish 
the spatial and temporal polarity necessary for directed migration.  Both extracellular and 
intracellular pH gradients have been observed in migrating cells [63, 64].  These pH 
gradients are achieved by localization of the sodium/proton exchanger 1 (NHE1) to the 
leading edge of migrating cells [63].  At the leading edge, NHE1 co-localizes with 
vinculin and talin, common focal adhesion markers [66], and regulates intracellular pH 
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by exchanging intracellular protons for extracellular sodium ions.  Its ion-transport 
activity is essential for establishing cell polarization, protrusion, and adhesion [65].   
 Due to the role of intracellular pH in cell migration and adhesion, the link 
between NHE1 and focal adhesion proteins, and the pH sensitivity of several proteins 
involved in migration, we investigated the pH sensitivity of the focal adhesion targeting 
(FAT) domain of focal adhesion kinase (FAK).  FAK is a non-receptor tyrosine kinase 
that localizes to focal adhesions upon integrin activation, and the C-terminal FAT domain 
is necessary for proper localization and subsequent activation of FAK [37, 38].  The FAT 
domain localizes FAK to focal adhesions at least partially via its interaction with the 
protein paxillin.  Phosphorylation of Y926 in the FAT domain has been linked to 
delocalization of FAK from focal adhesions.  In addition to its role in localization, the 
FAT domain is also involved in FAK-mediated signaling pathways.  In particular, 
phosphorylation of Y926 in the FAT domain has been shown to activate the MAPK 
pathway [19], which promotes angiogenesis [19] and tumor invasion and metastasis [47].  
Several labs have proposed that Y926 is not conducive to phosphorylation by Src based 
on its conformation [48, 49].  Therefore, the cell likely has a mechanism to promote 
phosphorylation of Y926, presumably by regulating the conformation of the region 
surrounding Y926.  In this paper, we investigate the role of pH on the conformation and 
dynamics of the FAT domain and how changes in pH affect phosphorylation.  While it is 
unclear if pH plays a role in regulation of the FAT domain in vivo, we have in vitro data 
that suggests that the structure, dynamics, and function of the FAT are sensitive to pH 
within physiological limits.   
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In this study, we investigated the role of pH on the phosphorylation, structure, and 
dynamics of the FAT domain in vitro.  Our data indicate that there are two sites of Src-
mediated phosphorylation in vitro: Y926, which has been shown to modulate FAK 
function by linking FAK to the MAPK pathway [19], and Y1008, which has no known 
biological function.  Interestingly, the pH-dependent phosphorylation profiles of these 
two sites are different.  Furthermore, Src-mediated phosphorylation of two synthetic 
peptides containing the sites of phosphorylation differ do not show a pH dependence, 
suggesting that it is the structure of the FAT domain and not Src activity that is affected 
by pH.  To explore the mechanism by which pH affects the FAT domain, we investigated 
the effect of pH on the structure and dynamics of the FAT domain using circular 
dichroism (CD) and NMR.  CD analyses reveal that the stability of the FAT domain is 
sensitive to pH; the FAT domain becomes less stable as the pH is increased from pH 5.5 
to pH 7.5.  NMR-derived short-range distance (NOE) and long-range orientation 
(residual dipolar coupling (RDC)) constraints do not support a pH-dependent structural 
change in the FAT domain; however, analysis of the 1H-15N HSQC spectra reveals pH-
dependent changes in backbone dynamics near the two sites of phosphorylation.  These 
data indicate that the backbone dynamics of the FAT domain are sensitive to pH and that 
pH-dependent changes in dynamics could lead to the observed changes in 
phosphorylation of the FAT domain in vitro.  It will be interesting to examine whether 
pH changes in vivo could regulate phosphorylation of the FAT domain and modulate 
FAK function.  
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Results/Discussion  
Phosphorylation as a function of pH 
 Phosphorylation of Y926 in the FAT domain has been implicated in excluding 
FAK from focal adhesions [73] and has been linked to promoting cell adhesion, 
migration, and invasion in vitro and metastasis in vivo [47].  Therefore, understanding 
how phosphorylation of Y926 affects FAK signaling on a molecular level may provide 
key insights into how this site is involved in FAK-mediated cancer progression.  We were 
interested in characterizing the phosphorylated species of the FAT domain because 
previous data from our lab and others have suggested that a structural rearrangement is 
necessary for recognition of the phosphorylated species by Grb2 [44, 49, 51].  We 
phosphorylated the FAT domain in vitro using purified Src kinase domain varying 
several conditions, one of which was pH, to optimize the levels of in vitro 
phosphorylation.  Levels of phosphorylation were detected by Western blot, and the site 
of phosphorylation was verified by mass spectrometry (MS).  As shown in Figure 2.1, 
the levels of FAT phosphorylation, as detected by both a general tyrosine and a phospho-
Y926-specific antibody increase as the pH is raised from 5.5 to 7.5.  This result is not 
surprising as the level of Src activity also increases from pH 5.5 to 7.5 as indicated by the 
increased levels of Src autophosphorylation (Figure 2.1).   
Figure 2.1: Detection of Phosphorylation 
by Western Blot 
The FAT domain was phosphorylated in vitro by 
Src kinase at pH 5.5, 6.0, 6.5, 7.0, and pH 7.5.  A. 
Detection of phosphorylation with a general 
phosphotyrosine antibody.  B. Detection of 
phosphorylation with a pY926 antibody.  C.  
Coomassie-stained gel showing consistent 
loading of the FAT domain.  Both the pTyr and 
the pY926 antibodies indicate higher levels of 
phosphorylation as the pH is increased. 
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 We verified the site of phosphorylation by MS.  Several MS techniques were 
employed to find a technique that was appropriate for determining the site of 
phosphorylation.  First, the full-length protein was analyzed by microelectrospray fourier 
transform ion cyclotron resonance mass spectrometry (µFTICR ECD MS) by Dr. Li Zhou 
in the laboratory of Dr. Xian Chen at UNC-CH.  After incubation with Src, the mass of 
the FAT domain increased by 80 Da, consistent with a single phosphorylation event.  A 
representative spectrum is shown in Figure 2.2A.  Typically, we observe approximately 
30% phosphorylation after overnight incubation with Src.  We used both bottom-up and 
top-down approaches to verify the site of phosphorylation.  For the bottom-up approach, 
the sample was subjected to trypsin digestion and analyzed by matrix-assisted laser 
desorption/ionization (MALDI) by Dr. Viorel Mocanu at the UNC Proteomics Core 
Facility.  For the top-down approach, the sample was analyzed by µFTICR ECD MS/MS 
by Dr. Li Zhou in the laboratory of Dr. Xian Chen (data not shown).  In both of these 
approaches, two phosphorylation sites were detected: Y926 and Y1008.  Figure 2.2B 
shows a representative spectrum from the MALDI analysis showing peptides that 
correspond to phosphorylation at Y926 and Y1008.  As stated above, analysis of the full-
length FAT domain by MS indicates a single phosphorylation event.  Therefore, even 
though there are two sites of phosphorylation, it appears that, under our conditions, the 
occurrence of a doubly phosphorylated FAT molecule is quite rare.  We currently do not 
have an explanation for this observation as the two phosphorylation sites are on opposite 
ends of the molecule, and it isn’t apparent why phosphorylation at one site should 
preclude phosphorylation at the other.  Alternatively, the fact that we detect only a singly  
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phosphorylated species could simply be a statistical phenomenon.  After incubation with 
Src overnight, only about 30% of the FAT domain is phosphorylated.  Therefore, one can 
imagine that, during the reaction, it is more likely for Src to encounter a non-
phosphorylated species than a phosphorylated species.  Furthermore, there are two ways 
to phosphorylate the non-phosphorylated species (at Y926 and at Y1008) whereas there is 
only one way to phosphorylate a singly phosphorylated species.  Therefore, 
phosphorylation of a previously phosphorylated species would be a rare event.  
 Because there were two sites of phosphorylation in vitro, we decided to quantify 
the relative levels of each site to determine whether Y926 was the major site of 
phosphorylation.  We subjected the phosphorylated samples to trypsin digestion and 
analyzed the peptides by reverse-phase LC/MS/MS.  To quantify the relative and absolute 
levels of phosphorylation at Y926 and Y1008, we spiked each sample with an internal 
standard: a synthetic phosphorylated peptide that mimics the tryptic peptide of each 
Figure 2.2: Detection of Phosphorylation 
by Mass Spectrometry 
A.  The FAT domain was phosphorylated in 
vitro at pH 5.5 (top) and pH 7.5 (bottom).  
Phosphorylation was detected by µFTICR ECD 
MS.  B.  The phosphorylated FAT domain was 
subjected to trypsin digestion and analyzed by 
MALDI MS.  Two phosphorylated peptides 
were detected, one containing Y926 (m/z 1645) 
and one containing Y1008 (m/z 1909).  These 
peptides were not detected in the 
unphosphorylated protein (data not shown).    
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phosphorylation site and contains a 13C-labeled valine residue in order to distinguish it 
from the sample peptide.  Because we observed missed-cleavage peptides by LC/MS, two 
tryptic peptides were synthesized for each phosphorylation site: Y926: 
SNDKV(pY)ENVTGL(V13C5)K-OH and V(pY)ENVTGL(V13C5)K-OH, Y1008:  
LAQQ(pY)(V13C5)MTSLQQEYK-OH and MKLAQQ(pY)(V13C5)MTSLQQEYK-OH.  
We phosphorylated the FAT domain in vitro at pH 5.5, 6.0, 6.5, 7.0, and 7.5 and analyzed 
the reactions by LC/MS using the synthesized peptides described above as internal 
standards at concentrations of 0.1, 0.2, 1, and 2 µg/mL.  Figure 2.3A-D shows the spectra 
of the peptide SNDKV(pY)ENVTGLVK-OH in the +2 charge state (m/z 823) and 
corresponding heavy internal standard (m/z 826) at different concentrations for the 
phosphorylation reaction at pH 5.5.  Figure 2.3E shows the calibration curve generated by 
plotting the log of the normalized peak area (area of sample/area of standard) versus the 
concentration of the internal standard for the +2 charge state of the peptide containing 
Y926 at pH 5.5.  The x-intercept of this graph represents the amount of phosphorylation in 
this sample.   
 A standard curve similar to the one shown in Figure 2.3E was generated for the +2 
and +3 charge states for peptides phosphorylated at Y926 and Y1008 at pH 5.5, 6.0, 6.5, 
7.0, and 7.5 to calculate the levels of phosphorylation at each site.  Figure 2.4 shows the 
level of phosphorylation as a function of pH for Y926 (red) and Y1008 (blue).  At pH 5.5, 
phosphorylation of Y926 is low (0.75 ± 0.04 µg/mL).  At pH 6.0, the levels of 
phosphorylation have increased to 1.6 ± 0.2 µg/mL.  The level of phosphorylation stays 
relatively constant from pH 6.0 to 6.5 before decreasing to 0.9 ± 0.5 µg/mL at pH 7.0 and 
0.4 ± 0.2 µg/mL at pH 7.5.  The pH profile for phosphorylation of Y1008 is slightly 
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different.  As seen for phosphorylation of Y926, phosphorylation of Y1008 increases as the 
pH is raised from 5.5 to 6.0 (from 0.5 ± 0.2 to 2.3 ± 0.1 µg/mL).  However, whereas 
phosphorylation of Y926 remains constant from pH 6.0 to 6.5, phosphorylation of Y1008 
increases to 2.85 ± 0.06 µg/mL.  As seen for Y926, phosphorylation of Y1008 decreases 
from pH 6.5 to 7.5 (0.5 ± 0.1 µg/mL at pH 7.5). 
Figure 2.3: Site-
specific 
quantitation of 
phosphorylation 
using internal 
standards 
A-D.  Spectra of the 
+2 charge state of the 
peptide containing 
phosphorylated Y926 
(m/z 823) and the 
heavy internal standard 
(m/z 826) at A. 0.1 
µg/mL, B. 0.2 µg/mL, 
C. 1 µg/mL, and D. 2 
µg/mL of the internal 
standard for the 
phosphorylation 
reaction at pH 5.5 E. 
Calibration curve used 
to calculate the level of 
phosphorylation of 
Y926 at pH 5.5.  The 
log of the normalized 
peak area (area of 
sample/area of 
standard) is plotted 
against the 
concentration of the 
internal standard.  The 
x-intercept of this 
graph represents the 
amount of 
phosphorylation in the 
sample.   
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 To distinguish whether the observed pH-dependent phosphorylation of the FAT 
domain is a result of the sensitivity of Src activity to pH or to pH-dependent changes in the 
FAT domain, we phosphorylated two synthetic peptides in vitro, one of which contains 
Y926 whereas the other contains Y1008, (SNDKV926YENVTGLVK-OH and 
MKLAQQ1008YVMTSLQQEYK-OH) at pH 5.5, 6.0, 6.5, 7.0, and 7.5 and subjected them 
to the same analysis as the full-length protein.  These peptides are expected to be 
unstructured, and therefore their structure should not be influenced by pH.  Figure 2.5 
shows the pH profile of phosphorylation of the synthetic peptides.  The phosphorylation of 
Y926 is relatively insensitive to pH whereas phosphorylation of Y1008 has a maximum 
value at pH 7.0.  It is unclear why the two peptides show different pH profiles.  One reason 
may be that the phosphorylation levels for Y926 are so much greater than those of Y1008 
(~100 fold) that any pH dependence is effectively masked.  For both peptides, we detected 
the nonphosphorylated peptide, indicating that the reaction did not go to completion; 
however, it is possible that the phosphorylation reaction with the Y926 peptide reached a 
maximum value and that, if we had taken samples at an earlier time point, pH-dependent 
changes in phosphorylation would have been observed.  However, one must also be careful 
not to read too much into the pH-dependence of Y1008.  The levels of phosphorylation are 
very low, and because we only conducted a one-point calibration, the quantitation of the of 
the peptides may not be as accurate as that of the full-length protein (Figure 2.4).  
Therefore, we contend that the pH dependent phosphorylation of the peptides is negligible, 
and even if one were to propose that Y1008 shows a pH optimum of 7.0, this value is 
different than the optimum pH in the context of the full-length protein (pH 6.5). Therefore, 
we conclude that the pH-dependent phosphorylation observed in the full-length FAT 
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domain is a result of a pH-dependent change in the conformation or dynamics of the FAT 
domain and not Src activity.  
 Interestingly, in the context of the peptide, Y926 is phosphorylated to a greater 
extent than Y1008 (~100 fold).  This result differs from the full-length protein in which 
levels of phosphorylation of the two sites were either comparable or Y1008 was the major 
site, depending on pH.  The fact that the Y926 peptide is phosphorylated to a greater extent 
than the Y1008 peptide is consistent with the fact that Y926 is the biologically relevant site 
of phosphorylation and that, in the absence of structure, the sequence surrounding Y926 is 
a better substrate for Src than the sequence surrounding Y1008. 
Figure 2.4: Site-Specific Quantitation of Phosphorylation 
The FAT domain was phosphorylated in vitro with Src kinase at pH 5.5, 6.0, 6.5, 7.0, and 7.5.  
The levels of phosphorylation at Y926 and Y1008 were quantified as described in the text.  In 
the context of the full-length protein, Y1008 is a better substrate for Src than Y926 as the 
levels of phosphorylation at Y1008 are either similar to or higher than the levels of 
phosphorylation at Y926 for all the pH values tested.  Optimum phosphorylation of Y926 
occurs at pH 6.0 whereas optimum phosphorylation of Y1008 occurs at pH 6.5.  
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Figure 2.5: Phosphorylation of Synthetic Peptides as a Function of pH  
Synthetic peptides containing Y926 and Y1008 of the FAT domain were phosphorylated in vitro as a 
function of pH and analyzed by mass spectrometry as described in the text.  A. Absolute quantitation of 
phosphorylation at Y926 and Y1008.  Absolute concentrations of phosphorylation at each site were 
calculated based on a one-point calibration with an internal heavy standard (0.5 µg/mL) and are 
reported as µg/mL.  B.  Relative levels of phosphorylation were determined based on the relative area 
of the sample peak and the internal standard peak and are reported as the fraction of sample 
area/standard area. 
 
A. 
B. 
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 Y926 is the only site of tyrosine phosphorylation in the FAT domain reported to 
modulate FAK function.  Whereas phosphorylation of Y1008 has been observed by mass 
spectrometry in full-length FAK purified from Sf9 cells [74], it is unclear whether 
phosphorylation of Y1008 is physiologically relevant.  As described above, we detected 
phosphorylation at Y926 using a commercially available phospho-Y926-specific antibody, 
as shown in Figure 2.1.  This antibody shows increasing levels of phosphorylation as the 
pH is increased from pH 5.5 to 7.5, which is similar to the trend observed with the general 
phosphotyrosine antibody.  These results contradict the MS results, which show that 
phosphorylation of Y926 reaches a maximum at pH 6.0.  Attempts to assess the specificity 
of pY926-specific antibodies using the phosphorylated peptides were unsuccessful, likely 
because the pY926 peptide did not bind to the nitrocellulose membrane.  It is possible that 
phosphorylation of Y1008 has been missed by previous studies that have used phospho-
Y926-specific antibodies.  Further experiments are necessary to determine whether 
phosphorylation of Y1008 is relevant in vivo.   
Circular Dichroism as a function of pH 
  Regardless of whether Y1008 is phosphorylated in vivo, the fact that the pH 
profile of phosphorylation of the full-length FAT domain differs from phosphorylation of 
a short peptide in vitro suggests a change in structure and/or dynamics between pH 5.5 
and 7.5 in the FAT domain that affects the accessibility of Y926 and Y1008 to Src 
kinase.  We therefore investigated the effects of pH on the secondary structure of the 
FAT domain by CD.  Figure 2.6 shows the far-UV CD spectra at pH 5.0, 5.5, 6.0, 6.5, 
7.0, and 7.5.  Each spectrum shows the minima at 222 and 208 nm characteristic of a 
helical protein.  While there are some differences in the intensity of the minima at 208 
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and 222 nm, the changes are subtle and do not show a trend as a function of pH.  It is 
likely that these differences are a result of errors in concentration rather than changes in 
secondary structure.  The CD signal is very sensitive to change in concentration; 
therefore, to determine whether pH affects the secondary structure of the FAT domain by 
CD, these data would have to be repeated and carefully adjusted for concentration.  
Overall, these data indicate that the FAT domain remains helical as the pH is changed. 
 We also investigated the pH-dependence of the thermal stability of the FAT 
domain by CD.  Figure 2.7 shows the thermal denaturation curves at pH 5.5, 6.0, 6.5, 
7.0, and pH 7.5, and the Tm values obtained from fitting the denaturation curves are 
shown in Table 2.1.  Interestingly, a sizable decrease in the Tm (approximately 16°C) is 
observed as the pH is increased from pH 5.5 to pH 7.5.  Because the CD data indicate 
Figure 2.6: Far-UV Spectra of the FAT Domain as a Function of pH 
Far-UV CD spectra of the FAT domain were collected at pH 5.0, 5.5, 6.0, 6.5, 7.0, and 7.5 from 260 
– 185 nm.  The minima at 222 and 208 nm are characteristic of a helical protein.  These data show 
that the FAT domain retains its helical content as the pH is changed. 
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that the FAT domain retains helical content at higher pH, the decrease in stability at 
higher pH is likely a result of changes in tertiary packing interactions rather than loss of 
secondary structure.   
1H-15N HSQC of the FAT Domain as a Function of pH 
 To evaluate pH-dependent structural changes on a per-residue basis, we collected 
Figure 2.7: Thermal Denaturation of the FAT Domain as a Function of pH 
Thermal denaturation was monitored by CD at 221 nm from 25-95°C at intervals of 0.5°C at pH 
5.0, 5.5, 6.0, 6.5, 7.0, and 7.5.  The melting curves show that the stability of the FAT domain is 
sensitive to pH; increasing the pH decreases the stability of the FAT domain.  
Table 2.1: Melting Temperature 
of the FAT Domain as a Function 
of pH 
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high-resolution 1H-15N HSQC spectra of 15N-enriched FAT-domain at various pH values.  
The analysis of the 1H-15N HSQC spectra as a function of pH was performed by Dr. Kirk  
Prutzman, a former graduate student in the laboratory of Dr. Sharon Campbell at UNC-
CH.  Figure 2.8A shows an overlay of the 1H-15N spectra at pH 5.5, 6.0, 6.5, 7.0, and 7.5.  
While some of the NH resonances show significant pH-dependent chemical shift changes 
(δ > 0.05 ppm) over the 5.5-7.5 pH range, other NH resonances remain unchanged.  
Figure 2.4B shows the weighted changes in chemical shift mapped onto the sequence of 
the protein.  Of interest is that several residues with significant changes in chemical shift 
are in helix-1, which contains one of the sites of phosphorylation, Y926.  In fact, one of 
the residues with the largest change in chemical shift is V928, which is near Y926.  
Furthermore, significant chemical shift changes are observed in the C-terminus of helix-1 
and in the loop between helices-1 and 2.  This region is of interest because dynamics in 
this region have been implicated in the regulation of phosphorylation of Y926 [48, 49].  
The fact that regions that show pH-dependent changes in chemical shift correlate to 
regions near Y926 and regions thought to regulate phosphorylation of Y926 (the loop 
between helices-1 and -2) supports the MS data that phosphorylation of Y926 is affected 
by pH. 
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 The largest chemical shift changes were observed for the three histidine residues 
(H981, H1026, H1053) in the FAT domain because histidine side chains typically have 
pK a values in the range of 6.0-6.5.  We were able to track the chemical shift changes of 
the NH resonances of the histidine residues as a function of pH to estimate the pKa of 
Figure 2.8: 1H-15N HSQC Spectra as a Function of pH:   
A. Overlay of 1H-15N spectra collected at pH 5.5 (black), 6.0 (red), 6.5 (green), 7.0 (blue), and 7.5 
(pink).  The chemical shifts of several peaks are affected by pH whereas others do not change.  The 
chemical shifts of the three histidine residues in the FAT domain (H981, H1026, and H1053) are 
circled.  B. The weighted changes in chemical shift from pH 5.5 to 7.5 were calculated.  Changes 
greater than 0.05 ppm (dashed line) were considered significant.  The histidine residues are shown in 
red. 
 
(ppm) 
(ppm) 
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each histidine within the FAT domain.  Figure 2.9 shows the titration profiles used to 
estimate pKa values for each histidine.  Estimated pKa values for H981, H1026, and 
H1053 are 5.8 ± 0.05, 6.2 ± 0.05, and 6.5, respectively.  Because these pKa values were 
distinct from each other, we proceeded to calculate the relative pK values of the residues 
that showed significant chemical shift changes.  Chemical shift changes that resulted in a 
pK value ± 0.15 pH units to one of the histidine pKa values were considered correlated to 
that histidine.  Figure 2.9 shows the residues whose pH-dependent changes in chemical 
shift correlated to specific histidine residues mapped onto the structure of the FAT 
domain.  H981 and residues correlated to it are shown in blue while H1026 and residues 
correlated to it are shown in red.  H1053 is shown in orange.  Titration of H981, located 
at the beginning of helix-3 correlates with the pH-dependent NH chemical shift changes 
of nearby residues, as expected.  However, there are also several residues distal to H981 
whose pH-dependent NH resonances correlate with this residue, including residues all 
along helix-2 and in the amino-terminus of helix-1, which contains Y926.  Titration of 
H1026, located in the middle of helix-4, correlates with the pH-dependent NH chemical 
shift changes of surrounding residues.  Interestingly, however, there are several residues 
in the C-terminus of helix-1 (V936, S940, S941, and S943) that titrate with H1026.  
Although the side chain of H1026 is mostly exposed to the solvent, this region of helix-1 
packs against helix-4 near H1026, and changes in helix-4 resulting from the titration of 
H1026 could affect residues in helix-1.  These residues (V936, S940, S941, and S943) are 
near the loop between helices-1 and 2, which has been proposed to be involved in 
regulation of phosphorylation of Y926 [48, 49].  H1053, the last residue in FAK, does not 
appear to interact with other residues within the FAT domain, and titration of H1053 does 
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not seem to be correlated to nearby residues.  There were also a number of peaks, notably 
in the N-terminal region of helix-2, whose pH-dependent chemical shifts do not track 
with a particular histidine residue.  pH-dependent NH chemical shift perturbations for 
these residues may be a result of de/protonation of both H1026 and H981 or of another 
titrating residue, possibly an aspartate or glutamate residue. 
 
 
 
 
 
Figure 2.9: Titration of the Histidine Residues.   
Titration profiles of each of the three histidine residues were used to calculate the pka of that 
residue (top).  B. Residues that titrate with the histidines residues were mapped onto the structure 
of the FAT domain.  Residues that titrate with H981 are shown in red.  They include resides near 
H981 as well as residues spanning helix-2 and at the N-terminus of helix-1.  Residues that titrate 
with H1026 are shown in blue.  These residues localize to the region near H1026 in helix-4 as 
well as the C-terminus of helix-1.    
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Investigation of pH-dependent structural changes by NOEs 
There are two possibilities for how pH could affect phosphorylation at Y926 and 
Y1008.  First, pH could affect the structure near these tyrosine residues, affecting the 
accessibility of the side chain to Src.  Second, pH could affect the dynamics of the FAT 
domain, which could render one site more susceptible to phosphorylation.  Indeed, 
dynamics of the hinge region between helix-1 and -2 have been proposed to play a role in 
phosphorylation of Y926 [49].  To investigate whether pH alters the structure of the FAT 
domain, we collected 15N- and 13C-edited NOESY spectra at pH 6.0 and pH 7.5.  Figure 
2.10 shows the carbon-based NOESY strips of the Cδ and Cε atoms of Y926 (A-D) and 
Y1008 (E-H) at pH 6.0 and pH 7.5.  The NOEs observed from the Cδ and Cε atoms of 
Y926 and Y1008 are very similar at pH 6.0 and pH 7.5, suggesting that pH does not 
change the local environment of these tyrosine residues and therefore probably does not 
have a major effect on the structure of the FAT domain.   
Investigation of pH-dependent structural changes by RDCs 
To further investigate pH-dependent structural changes in the FAT domain, we 
collected NH RDCs at pH 6.0 and 7.5.  Figure 2.11 shows the correlation between RDC 
values of two datasets collected at pH 6.0, two datasets collected at pH 7.5, and a 
comparison of a dataset collected at pH 6.0 and at pH 7.5.  The correlation between the 
RDC values at pH 6.0 and pH 7.5 was 0.85, which is not significantly different from the 
correlation between two datasets collected at pH 6.0 (0.88) or two datasets collected at 
pH 7.5 (0.90).  Because neither the NOESY data nor the RDC data indicate that pH 
affects the structure of the FAT domain, we investigated the role of pH in altering the 
dynamics of the FAT domain.   
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Figure 2.10: NOEs from the Sidechain of Y926 and Y1008: 
13C-edited NOEs were collected on the FAT domain at pH 6.0 and 7.5.  A. NOEs from the 
Hδ of Y926 at pH 6.0. B. NOEs from the Hδ of Y926 at pH 7.5.  C. NOEs from the Hε of 
Y926 at pH 6.0.  D. NOEs from the Hε of Y926 at pH 7.5.  E. NOEs from the Hδ of Y1008 
at pH 6.0.  F. NOEs from the Hδ of Y1008 at pH 7.5.  G. NOEs from the Hε of Y1008 at pH 
6.0.  H. NOEs from the Hε of Y1008 at pH 7.5.  There are no major differences in the NOEs 
between pH 6.0 and 7.5, indicating that pH does not cause a major structural change in these 
regions.   
ppm ppm ppm ppm 
ppm ppm ppm ppm 
ppm ppm ppm ppm 
ppm ppm 
ppm ppm 
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1H-15N HSQC Analyses Suggest pH-Dependent Changes in FAT Domain Dynamics.  
 While we were unable to detect any significant pH-dependent structural change, 
there are several residues in the 1H-15N HSQC spectra that show changes in NH peak 
intensity as a function of pH, suggesting a pH-dependent change in backbone dynamics.  
In particular, as the pH is increased from pH 6.0 to pH 7.5, several residues show 
significant decreases in intensity due to peak broadening.  Broadening of the NH 
resonances as the pH is increased can be difficult to interpret because a variety of 
Figure 2.11: Residual Dipolar Couplings as a Function of pH: 
Residual dipolar couplings were collected on the FAT domain at pH 6.0 and pH 7.5.  A. 
Comparison of two independent datasets collected at pH 6.0.  B. Comparison of two independent 
datasets collected at pH 7.5.  C. Comparison of RDCs collected at pH 6.0 and pH 7.5.  D. 
Comparison of second datasets collected at pH 6.0 and pH 7.5.  
 
   
 
 
40 
mechanisms can contribute to this broadening, the most pertinent of which are pH-
dependent differences in conformational dynamics (exchange between two or more 
states) and chemical exchange (an increase in exchange between the amide proton and 
the solvent).  As expected, the N- and C-termini NH resonances are severely broadened at 
higher pH, likely due to an increase in base-catalyzed amide exchange.  These residues 
are located in unstructured regions and consequently more exposed to the solvent.  There 
are also several residues in the turn between helices-3 and -4 and in the N-terminus of 
helix 4 that broaden as the pH is increased.  Figure 2.12 shows the change in linewidth 
mapped onto the sequence of the FAT domain.  In this figure, a negative change indicates 
broadening at pH 7.5 whereas a positive change indicates narrowing.  Several resides 
near Y1008, one of the sites of phosphorylation, show an increase in linewidth as the pH 
is increased.  However, as stated above, it is difficult to distinguish whether broadening 
in this region is due to an increase in solvent exchange, as these residues are in a turn and 
exposed to the solvent, or to changes in dynamics. 
 In addition to peaks that broaden as the pH is increased, there are also several 
peaks that increase in intensity due to a decrease in linewidth upon increasing the pH 
from 6.0 to 7.5.  Interestingly, several peaks that localize to the end of helix-1, the 
beginning of helix-2, and the loop region in between these helices show a decrease in 
linewidth as the pH is increased (Figure 2.12).  There are also several peaks that span 
helix-3 that narrow as the pH is increased.  Figure 2.13 shows several peaks of interest as 
a function of pH.  I943, A946, and M954 are all located in and around the hinge region.  
The observed narrowing of peaks in the hinge region of the FAT domain is likely due to a 
pH-dependent change in dynamics from the intermediate timescale where peaks are 
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broader, to a faster timescale, where peaks become sharper.  Several of these residues 
were previously shown to be sensitive to temperature-dependent broadening [49], and 
dynamics in this region were postulated to affect phosphorylation of Y926 in helix-1 [48-
50].  The fact that peaks in the hinge region show pH-dependent dynamics supports our 
phosphorylation data that shows that phosphorylation of Y926 is dependent on pH in the 
context of the full-length FAT domain.   
 
 
 
 
 
 
 
 
 
 
 
 
Investigation of pH-dependent dynamics – Backbone Relaxation 
Because the pH-dependent 1H-15N HSQC data suggest changes in dynamics as a 
function of pH, we further investigated this effect by collecting T1, T2, and heteronuclear 
NOE (HetNOE) datasets at pH 6.0 and pH 7.5.  These measurements are sensitive to 
backbone dynamics on the ps-ns timescale as well as the ms timescale.  The relaxation  
Figure 2.12: Changes in NH Linewidth as a Function of pH: 
1H-15N spectra were collected at pH 6.0 an pH 7.5.  The linewidths (proton and nitrogen) 
were measured using the program Sparky.  Differences (pH 6.0 – pH 7.5) in linewidth are 
plotted on the sequence of the FAT domain.  The secondary structure of the FAT domain is 
shown below the graph. 
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data was fit to a model-free formalism [75] to obtain the overall correlation time (τm) and 
the order parameters S2 and τe, which measure the rigidity of the N—H bond and the 
internal correlation time, respectively.  pH did not affect the overall correlation time (τm) 
of the protein, which is generally dependent on the overall size and shape of the 
molecule.  The τm was determined to be 11.3 ns at pH 6.0 and pH 7.5.  This value is 
slightly higher than expected for a protein this size (~9.5 ns).  This discrepancy is likely 
due to the fact that the τm was determined assuming isotropic tumbling.  However, the 
FAT domain is not a spherical molecule (60 Å x 20 Å x 20 Å [48]), and therefore some 
error would be expected in the isotropic τm.  Our interest here is to compare the rotational 
correlation time at pH 6.0 and 7.5, thus a relative comparison indicates little change in τm.  
Figure 2.13: Representative Peaks that Narrow from pH 6.0 to pH 7.5: 
Several peaks in the 1H-15N HSQC of the FAT domain increase intensity as the pH is raised from 
6.0 to 7.5.  Shown above are four such peaks at pH 6.0 (red), pH 6.5 (blue), pH 7.0 (green), and pH 
7.5 (purple).  M954, I943, and A946 are located in and around the hinge region between helices-1 
and -2 whereas L991 is in helix-3.  These data indicate that the hinge region experiences pH-
dependent changes in backbone dynamics.  
(ppm) (ppm) 
(ppm) 
(ppm) 
(ppm) 
(ppm) 
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No discernable difference was observed in the S2 order parameter as a function of pH.  
As expected, the S2 values are near 0.9 in the structured regions of the proteins and 
decrease to around 0.8 in the loops and turns.  Residues in the N- and C-termini are not 
visible by NMR at pH 7.5 and have lower S2 values at pH 6.0 (~0–0.6), as these residues 
are less structured relative to those in the helix bundle domain, are more exposed to the 
solvent, and likely undergo enhanced solvent-mediated chemical exchange.  No 
difference in τe is observed as a function of pH. 
It may not be surprising that we see little difference in S2 or τe as a function of pH 
because these values are sensitive to backbone motions on faster timescales (ps-ns) than 
the overall correlation time of the FAT domain.  Thus, it is possible that the dynamic 
changes that occur as a function of pH occur on a slower timescale (µs-s) and may 
involve the side chains.  
While the 15N-based T1, T2, and HetNOE relaxation measurements provide 
backbone dynamic information on the ps-ns timescale, the measurements are also 
sensitive to motions on slower timescales (µs-ms).  Indeed, several residues appear to be 
undergoing motion on these slower timescales, as indicated by contributions by Rex in the 
model-free fitting.  At pH 6.0, there are three residues in helix-1, K924 (which is not 
visible at pH 7.5), I937, and A946, that experience slower µs-ms timescale dynamics.  
The intensity of the A946 NH resonance also increases in the 1H-15N HSQC spectrum as 
the pH is increased, which provides further evidence that dynamics in this region are 
susceptible to changes in pH.  A946 is in a putative “hinge region”, the loop between 
helices 1 and 2.  It has been postulated that dynamics in this region due to strain caused 
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by a series of proline residues modulate a helix-coil transition in helix-1 that regulates 
phosphorylation of Y926 [49].   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.14: Backbone Dynamics of the FAT Domain as a Function of pH: 
15N-based T1, T2, and HetNOE data were collected at pH 6.0 and pH 7.5 
and fit a model-free formalism to obtain S2 order parameters (top).  Three 
residues at pH 6.0 also showed evidence of µs-ms timescale motion, 
apparent in the Rex 
Y1008 
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Investigation of pH-dependent dynamics by CPMG-based Relaxation Dispersion 
Because it appears that dynamics in the FAT domain are sensitive to pH on the 
µs-ms timescale, we collected further NMR experiments that are sensitive to dynamics on 
this timescale.  One method to quantify dynamics on the µs-ms timescale is by Carr-
Purcell-Meiboom-Gill relaxation dispersion experiments.  These 1H-15N HSQC-based 
experiments allow one to measure dynamics on the µs-ms timescale by introducing a 
series of spin-echoes into the sequence (τ - 180° - τ).  If there are conformational 
dynamics in the protein that occur on the same order as the frequency of the spin-echo 
sequence, the 180° pulses become less effective at refocusing the magnetization, leading 
to a decay in the observed signal.  By measuring peak intensity as a function of τ, one can 
obtain kinetic and thermodynamic information on the exchange process and on weakly-
populated conformations of the protein, respectively.  The ability to observe dynamics by 
relaxation dispersion depends on both the timescale of the dynamics and on the 
population of lowly-populated species (for review see [76]).  We collected CPMG-based 
relaxation dispersion experiments at pH 6.0 and pH 7.5 at several temperature values 
(15°C, 25°C, 37°C, and 45°C) at τ = 0, 0.556, 5, and 10 ms.  Figure 2.15 shows the 
difference in R2,eff between τ10 and τ0.556.  Generally, a difference of 8-10 Hz provides 
enough sensitivity to fit the relaxation curves.  However, as seen in Figure 2.15, the 
differences in R2,eff are on the order of 2-3 Hz and are too small to quantify. 
Investigation of pH-dependent dynamics by CLEANEX-PM 
Another method to examine dynamics on the µs-ms timescale is hydrogen 
exchange measured by the CLEANEX-PM pulse sequence [77].  In this 1H-15N HSQC- 
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based experiment, the water signal is saturated, a short delay is applied (0-55 ms), and the 
protein signal is observed by an 1H-15N HSQC sequence.  Only the residues that 
exchanged with water during the delay period will be observable.  As the delay is 
increased, the intensity of the observable resonances will increase, and rates of exchange 
can be acquired.  Processes that affect the solvent accessibility of a particular residue 
would be expected to have an effect on the rate of solvent exchange.    
We collected CLEANEX-PM spectra at pH 6.0, 6.5, 7.0, and 7.5 to investigate 
dynamics on slower timescales.  Figure 2.16 shows the residues observed at each pH 
value.  Many of the peaks observed in the CLEANEX-PM spectrum at low pH values 
(pH 6.0 and 6.5) are in the termini and loops, which are not visible at pH 7.5.  This is 
expected because these residues are in unstructured regions and therefore readily 
Figure 2.15: Delta R2 Values from CPMG-Based Relaxation Dispersion 
CPMG-based relaxation dispersion data were collected at 37°C at pH 6.0 with delay times (τ) of 0, 
0.556, and 10 ms.  The R2 for each delay was calculated by the following equation: R2 = -
(1/0.04)Ln(I0/Iτ ).  The delta R2 (R210 – R20.556) was plotted as a function of the sequence of the FAT 
domain.  The differences in R2 are too small to quantify relaxation dispersion 
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exchange with the solvent.  Furthermore, many of the peaks in the CLEANEX-PM 
spectrum at pH 7.5 are not observed at pH 6.0.  Interestingly, the peaks that appear at pH 
7.5 are localized to helix-1, which was previously shown by conventional hydrogen 
exchange experiments to be less protected than the other three helices [50].   
Hydrogen exchange is base catalyzed at pH values above 4.0; therefore, the 
increase in the observable peaks at pH 7.5 could be either a result of a change in solvent 
accessibility of these residues due to a change in dynamics or an increase in solvent 
exchange due to the increase in pH.  To distinguish between these two processes, it is 
necessary to monitor the pH dependence of the rate of exchange for a particular residue 
and see if it deviates from the expected 10-fold increase in exchange per pH unit.  A 
deviation in this dependence would suggest that there are other processes, i.e., changes in 
dynamics, that affect the solvent accessibility and therefore rate of solvent exchange of a 
particular residue.  However, we were not able to conduct such a comparison because we 
were not able to visualize many peaks at more than one pH value. 
Figure 2.16: CLEANEX Experiments of the FAT Domain as a Function of pH: 
CLEANEX data were collected on the FAT domain at 37°C at pH 6.0, 6.5, 7.0, and 7.5.  Shown 
in red are the residues that were detected in the CLEANEX spectrum at the indicated pH.  Most 
of the residues localize to the termini and loops, and as expected, the number of residues detected 
increases as the pH is increased. 
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Identifying Residues Whose Titration Correlates with the pH-Dependent Stability 
The pH-dependent changes in phosphorylation, stability, and dynamics that we 
observe in the FAT domain beg the question what is causing this pH sensitivity.  To 
answer this question, we have mutated several residues in the FAT domain and assessed 
their sensitivity to pH by measuring the thermal stability by CD.  First, because histidine 
side chains typically have a pKa at about pH 6.0, these residues are likely candidates for 
the cause of the observed pH sensitivity.  There are three histidine residues in our 
construct, and we have made single point mutations in which each of these residues has 
been mutated to alanine.  The experimental work with the histidine mutants was 
conducted by Dr. Kirk Prutzman, a graduate student in the laboratory of Dr. Sharon 
Campbell at UNC-CH.  Thermal melts monitored by CD at 221 nm indicate that none of 
single histidine mutants are able to completely compensate for the pH-dependent change 
in stability (data not shown).  It is possible that the pH-dependent change in stability is 
caused by an additive effect of the titration of all three histidines.   
Another explanation for the pH-dependent change in stability is anomalous 
titration of an aspartate or glutamate residue.  This would be unusual, but not unheard of.  
While the canonical pKa for the side chain of aspartate and glutamate is around pH 4, pKa 
is very sensitive to the local environment, and a pKa as high as 6.7 has been detected for 
an glutamate residue in the glycoprotein CD2 [78] and 6.6 for an aspartate residue in a 
mutant of PGB1 [79].  Based on the structure of the FAT domain, we individually 
mutated two asparate residues and one glutamate residue to alanine (D994A, E949A, 
D1040A).  D994 is in the middle of helix-3 in the FAT domain.  In the three-dimensional 
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structure of the FAT domain, D994 is in between E997 and D1031.  We reasoned that the 
concentration of negative charge in this region might promote protonation of D994, 
which could allow it to form hydrogen bonds with the side chains of E997 or D1031.  
Second, we mutated E949, which is in the loop between helices-1 and -2.  In the NMR 
structure of the FAT domain, solved at pH 6.0 [49], E949 is in an unstructured region 
and, in some of the models, the side chain is packed into the core of the helix bundle 
whereas in the crystal structure solved at pH 7.0 [48], E949 is in the beginning of helix-2 
and the side chain is exposed to the solvent.  If the side chain of E949 is able to pack into 
the core of the helix bundle, as observed in several of the NMR models, then burial of the 
negative charge would likely promote protonation of the side chain.  However, it should 
be mentioned that the loop between helices-1 and -2 contains several proline residues; 
therefore, the NMR data in this area is sparse, and the conformational variability of E949 
may be due to the lack of restraints in this region.  Finally, we also mutated D1040 in 
helix-4 of the FAT domain.  The side chain of D1040 faces helix-1 near Y926 and, in the 
crystal structure [48], is involved in a salt bridge with R920.  In the NMR structure, 
however, this salt bridge is not observed, perhaps due to a lack of data near R920, which 
is unstructured, and the R920 resonance is broadened in the 1H-15N HSQC spectrum, 
making it difficult to acquire restraints in this region.  However, in the NMR structure 
[49], the side chain of D1040 is buried by the N-terminus of the protein, which, due to the 
lack of NMR data in this region, may or may not be observed in the actual protein.    
We individually mutated D994, D1040, and E949 to alanine and measured the 
thermal stability at pH 6.0 and pH 7.5 by CD.  As observed for the histidine mutants, 
none of the aspartate/glutamate mutants were able to abrogate the pH-dependent stability.  
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Figure 2.17 shows the thermal denaturation curves for D994A, E949A, and D1040A at 
pH 6.0 and pH 7.5.  The melting temperatures obtained from fitting the curves are shown 
in Table 2.2.  Currently, the molecular basis for the pH sensitivity observed in the FAT 
domain remains elusive.  It is possible that one of the aspartate or glutamate residues that 
we did not mutate is titrating and causing the pH sensitivity, or perhaps the pH sensitivity 
is not due to titration of a single residue and is the result of a more complex phenomenon.  
Finally, it should also be noted that whatever mechanism promotes the pH-dependent 
stability may not be the same mechanism that affects the dynamics and phosphorylation.  
Currently, we have only tested the histidine and aspartate/glutamate mutants with regard 
to pH-dependent stability as we do not have a straightforward method to assess 
phosphorylation, and it is possible that while these mutants do not abrogate the pH-
dependent stability, they may affect the pH-dependent changes in phosphorylation.   
Conclusion 
 Phosphorylation of Y926 in the FAT domain has been shown to play a role in 
FAK signaling and localization.  In particular, phosphorylation has been linked to 
promoting cell adhesion, migration, and invasion in vitro and metastasis in vivo [47].  
However, the mechanism by which phosphorylation is regulated in vivo remains to be 
elucidated.  While it has been speculated that a conformational change is necessary for 
phosphorylation of Y926 [48, 49], what regulates this conformational change in vivo is 
unknown. 
 In this study, we have shown that phosphorylation of Y926 by Src is pH 
dependent in vitro.  Furthermore, we have demonstrated that Src is able to phosphorylate  
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Y1008 in vitro and that phosphorylation at this site is also pH dependent.  
Phosphorylation of peptides containing Y926 and Y1008 do not show the same pH 
dependence as phosphorylation of the full-length protein, suggesting that the observed pH 
dependence of phosphorylation is primarily a result of changes in the structure and/or 
dynamics of the FAT domain and not Src activity.  Furthermore, in the context of the 
peptides, Y926 is phosphorylated approximately 100 times more than Y1008 whereas in 
Figure 2.17: Thermal Denaturation of Aspartate and Glutamate Mutants: 
The FAT domain and mutants were dialyzed in CD buffer at pH 6.0 (right) and pH 7.5 (left).  
Thermal denaturation was measured by monitoring the CD signal at 221 nm at intervals of 0.5°C. 
Table 2.2: Melting Temperatures of Aspartate/Glutamate Mutants of the 
FAT Domain 
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the context of the full-length protein, the levels of phosphorylation at the two sites are 
either comparable or favor Y1008, depending on pH.  These results suggest that while the 
sequence surrounding Y926 is conducive to phosphorylation by Src, in the full-length 
FAT domain the conformation of Y926 is not.  Y926 is in a helix, and it has been 
speculated that its conformation is not conducive to phosphorylation [48, 49].  Indeed, a 
construct containing helix-1 of the FAT domain fused to GST is phosphorylated to a 
greater extent in vitro than the full-length FAT domain [49], indicating that the 
conformation of Y926 in the full-length FAT domain does not favor phosphorylation.  On 
the other hand, Y1008 is in a more appropriate conformation for phosphorylation in the 
full-length FAT domain even though the sequence is not as optimized for Src recognition 
as the sequence surrounding Y926.  Y1008 is at the end of helix-3 and begins the turn 
between helices-3 and -4.  Based on our phosphorylation results, the conformation of 
Y1008 in the full-length FAT domain is more favorable for recognition by Src than that 
of Y926.  These results highlight the two basic determining factors for kinase recognition 
and subsequent phosphorylation: sequence and conformation.  While it is well known 
that a potential site of phosphorylation must possess a suitable sequence and 
conformation for recognition by a kinase, our results present an interesting example in 
which one site (Y926) seems to be optimized for sequence but not conformation whereas 
the other site (Y1008) is optimized for conformation but not sequence.  The fact that 
Y926 is the biological site of phosphorylation may suggest that, in vivo, sequence is more 
important than conformation for recognition by Src.  However, the use of non-specific 
phosphorylation antibodies and peptide libraries to investigate sites of phosphorylation 
and determine kinase consensus sequences may have resulted in Y1008 being overlooked 
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as a possible substrate for Src.  Further work is necessary to determine whether Y1008 is 
phosphorylated in vivo. 
 Our phosphorylation data suggest that the conformation of Y926 is sensitive to 
pH, which affects phosphorylation at that site.  Our CD and NMR data suggest that the 
FAT domain does not experience a major structural change as a function of pH.  
Therefore, either the structural change is minor or pH primarily affects dynamics and not 
structure.  The pH-dependent changes in linewidth observed in the 1H-15N HSQC spectra 
indicate that the backbone dynamics of the FAT domain are sensitive to pH.  In 
particular, the region between helix-1 and -2, the hinge region, in which conformational 
dynamics have been proposed to regulate phosphorylation of Y926 [49], shows pH-
dependent dynamics on the µs-ms timescale, supporting our data that show that 
phosphorylation of Y926 is pH dependent.  We were not able to quantify the dynamics of 
the FAT domain by relaxation dispersion experiments.  In order to quantify dynamics 
with these experiments, the dynamics must be in the proper time scale, and the lowly-
populated state of the protein must be present at at least 0.5%.  NMR-based hydrogen 
exchange studies of the excited state of the FAT domain estimate that the lowly-
populated state is only present at about 0.1% [51].  Therefore, it may not be possible to 
quantify the dynamics in the hinge region. 
     We attempted to determine the titrating residue that was the cause of the pH 
dependent stability and dynamics.  After individually mutating each histidine residue, 
two asparate residues, and one glutamate residue, we were unable to determine the cause 
of the pH sensitivity.  It is possible that the pH dependent changes we see are due to 
titration of several residues, and therefore single point mutations cannot abrogate this 
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effect.  Alternatively, the pH-dependent effects that we observe may be due to titration of 
a residue that we have not investigated.  If we could determine the cause of the pH-
dependent effect, we could potentially make a pH-insensitive mutant of the FAT domain 
that could be used in vivo to elucidate whether pH regulates the FAT domain in vivo.  
While more work remains to be done until we can test this hypothesis, our current pH-
dependent phosphorylation data is consistent with the proposed function of 
phosphorylation at Y926.  According to our data, phosphorylation of Y926 is weak under 
basic conditions; we observe the lowest levels of Y926 phosphorylation at pH 7.5.  
Therefore, at the leading edge of migrating cells, which is slightly more basic than the 
trailing edge, Y926 is less likely to be phosphorylated.  The intracellular pH becomes 
more acidic towards the trailing edge of the cell, and according to our data, 
phosphorylation at Y926 increases as the pH is decreased from pH 7.5 to pH 7.0.  
Therefore, one might speculate that Y926 becomes phosphorylated at the trailing edge of 
cells due to the difference in pH between the leading and trailing edges.  This hypothesis 
is consistent with data that demonstrate that Y926 delocalizes FAK from focal adhesions 
and promotes focal adhesion turnover [73].  In summary, our data support a model in 
which nonphosphorylated FAK localizes to focal adhesions at the leading edge of 
migrating cells where the pH is more basic than the overall intracellular pH.  As the cell 
migrates, the leading edge becomes the trailing edge, and the pH becomes more acidic.  
These conditions promote phosphorylation of Y926 in the FAT domain, which causes 
delocalization of FAK from focal adhesions, focal adhesion turnover, and subsequently 
cell migration.   
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 Methods 
Expression and Purification of wild type and mutant FAT 
 The FAT domain construct used in these studies contains residues 920 to 1053 of 
chicken FAK plus a 12 amino acid N-terminal linker (bold): 
(GSPGISGGGGGIRSNDKVYENVTGLVKAVIEMSSKIQPAPPEEYVPMVKEVGL
ALRTLLATVDESLPVLPASTHREIEMAQKLLNSDLAELINKMKLAQQYVMTSLQ
QEYKKQMLTAAHALAVDAKNLLDVIDQARLKMISQSRPH).  The FAT domain 
was expressed as a GST fusion protein as previously described.  The pGEX-KG plasmid 
containing the GST-FAT sequence was transformed into BL21(DE3) E. coli cells for 
protein expression.  Bacteria were grown in LB-Amp at 37°C to an OD600 ~ 0.6.  
Expression was then induced by the addition of 0.5 mM isopropyl β-D-1-
thiogalactopyranoside (IPTG), and cells were grown for a further three to five hours 
before harvesting by centrifugation.  Cells were resuspended in lysis buffer (20 mM Tris 
pH 7.5, 10% glycerol, 10 mM dithiothreitol (DTT), 150 mM NaCl) and lysed by 
sonication (5 sec. on 5 sec. off for a total of one hour).  The lysate was centrifuged at 15k 
rpm for 70 min. to remove insoluble cell debris.  The supernatant was added to 
glutathione-agarose (GSH) beads and incubated at 4°C overnight.  The beads were 
washed once with lysis buffer and two times with thrombin cleavage buffer (50 mM Tris 
pH 8.0, 150 mM NaCl, 2.5 mM CaCl2, 0.1% β-mercaptoethanol (BME)).  Typically, 
about 0.5 units/mL of thrombin were added to the beads to cleave the fusion protein.  The 
beads were incubated with thrombin at room temperature overnight and then washed 
three times with thrombin cleavage buffer.  The supernatants of these washes were 
combined, and thrombin activity was inhibited by the addition of p-aminobenzamidine 
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agarose beads, which were subsequently removed by centrifugation.  The protein was 
dialyzed into S-column buffer A (25 mM NaPO4 pH 5.5, 0.01% NaN3) and purified by 
cation-exchange chromatography on a mono S column and eluted with a gradient of 0 – 1 
M NaCl over 200 mL.  The protease inhibitors PPACK (1 µM) and pefablock (0.5 
mg/mL) were added to the purified protein to prevent degradation.  
 Protein concentration was measured by diluting the protein in a final 
concentration of 6 M guanidinium hydrochloride and measuring the absorbance at 280 
nm.  The concentration was calculated using the calculated extinction coefficient at 280 
nm (5120 M-1cm-1 for wild type and 4470 M-1cm-1 for the mutants) from the ProtParam 
tool on the ExPASy proteomics server [80]. 
Mutagenesis 
The construct expressing the GST-wtFAT domain fusion protein has been 
described elsewhere [49].  The Quikchange mutagenesis protocol (Stratagene) was used 
to incorporate point mutations into positions 994, 1040, and 949.  The following primers 
were used to make the desired mutants (bold indicates site of mutation): 
D994A 
5’ G AAA CTG CTG AAC TCT GCG CTG GCT GAG CTC ATT AAC 3’ 
D1040A 
5’ CTG GAT GTC ATC GCT CAA GCC AGA CTG 3’ 
E949A 
5’ AA ATA CAG CCA GCT CCG CCA GCG GAG TAC GTG CCA AT 3’ 
 Quikchange reactions were digested with DpnI at 37°C to remove any template 
DNA and transformed into DH5α E. coli cells.  Single colonies were chosen and 
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incubated in LB-Amp overnight, and plasmid DNA was purified using the Qiagen 
Miniprep kit.  The mutation was verified by sequencing by GENEWIZ (USA) using the 
pGEX 5’ sequencing primer (5’ GGGCTGGCAAGCCACGTTTGGTG 3’). 
Src Expression and Purification 
 Several Src kinase constructs were received from various sources.  Baculovirus-
expressed full-length human Src was a gift from BioSource (PHO3131).  Also, several 
bacterially-expressed constructs were used.  Kinase domain (KD Src) only and full-length 
(FL Src) chicken c-Src constructs were received from the lab of Dr. John Kuriyan while 
full-length and ΔSH3 human Src constructs were received from Dr. Gonquin Sun [81]. 
Because of difficulties in purifying and achieving consistent phosphorylation with the 
full-length Src constructs, all studies reported in this paper were conducted with KD Src.   
 The expression and purification of the chicken c-Src constructs is similar to that 
in Seeliger et al. with a few modifications [82].  Bacteria were transformed with two 
plasmids.  One plasmid contains the specified Src sequence while the other plasmid 
contains a YopH phosphatase sequence.  Tyrosine kinases are notoriously difficult to 
express in bacteria.  It is thought that expressing a phosphatase with the kinase will 
negate the effect of the kinase [81, 82].  Bacteria were grown in LB with 50 µg/mL 
kanamycin and 50 µg/mL streptomycin at 37°C to an OD600 ~ 0.800.  The temperature 
was reduced to 18°C, and, after one hour, expression was induced by the addition of 0.2 
mM IPTG.  Cells were shaken at 18°C overnight and then harvested by centrifugation.  
Cells were resuspended in lysis buffer (50 mM Tris pH 8.0, 500 mM NaCl, 5% glycerol, 
25 mM imidazole) and lysed by sonication.  The lysate was centrifuged at 15,000 rpm for 
70 min to remove cell debris, and the cleared lysate was loaded onto a Ni2+ affinity 
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column that had been pre-equilibrated with lysis buffer.  The column was washed with 
two column volumes of lysis buffer with 50 mM imidazole, and protein was eluted with 
lysis buffer with 300 mM imidazole.  Ten 5-mL fractions were collected from the Ni2+ 
column and analyzed by SDS-PAGE.  The fractions containing Src were pooled and 
dialyzed into 20 mM Tris pH 8.0, 100 mM NaCl, 5% glycerol, and 1 mM DTT with 
tobacco etch virus (TEV) protease at 4°C overnight to cleave the 6X His tag.  The protein 
was then re-loaded onto the Ni2+ affinity column pre-equilibrated with lysis buffer to 
remove the TEV, which contains a His tag.  The first 20 mL of the flow-through were 
collected, and the presence of Src in the flow-through was verified by SDS-PAGE.  
Protein concentration was determined by measuring the absorbance at 280 nm (ε = 52745 
M-1cm-1) as calculated by the ProtParam tool on the ExPASy proteomics server [80].  A 
50% glycerol stock of the purified protein was made, and 5-10 µL aliquots were stored at 
-20°C until use.   
In vitro Phosphorylation of the FAT domain and Synthetic Peptides 
 Purified full-length FAT domain was dialyzed into phosphorylation buffer (100 
mM MES (pH 5.5, 6.0, 6.5) or 100 mM HEPES (pH 7.0, 7.5), 5.0 mM MgCl2, 1 mM 
DTT, 0.01% NaN3).  Each reaction contained 0.5 mg/mL FAT domain, ~ 1 µM Src, and 
0.5 mg/mL ATP.  Reactions were incubated at 37°C overnight in an eppendorf tube with 
a 2 kDa MW cutoff bottom floating in 100 mL of phosphorylation buffer to ensure that 
the pH remained constant throughout the course of the reaction.   
 Two synthetic peptides (SNDKVYENVTGLVK-OH and 
MKLAQQYVMTSLQQEYK-OH, containing Y926 and Y1008, respectively) were 
synthesized by Dr. Krzysztof Krajewski in the laboratory of Dr. Brian Strahl at UNC-CH.  
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The peptides were dissolved in water and diluted with 10X phosphorylation buffer to a 
final concentration of 0.56 mg/mL in a final volume of 100 µL.  Src (1 µL of 5 mg/mL) 
was added to each reaction, and the reactions were incubated at 37°C for one hour.  In 
total, ten reactions were performed: peptide containing Y926 at pH 5.5, 6.0, 6.5, 7.0, and 
7.5 and peptide containing Y1008 at pH 5.5, 6.0, 6.5, 7.0, and 7.5.  Samples were kept at 
-20°C until analysis. 
Detection of Phosphorylation in Full-Length FAT: Western Blot  
 After the reaction, phosphorylation reactions of the full-length FAT domain were 
separated by SDS-PAGE and transferred to a nitrocellulose membrane for 30 min. at 70 
V.  The membrane was blocked for one hour at room temperature with 5% bovine serum 
albumin (BSA) in tris-buffered saline plus tween (TBST) and then incubated with the 
primary antibody overnight at 4°C (1:5000 dilution, 5% BSA).  Phosphorylation was 
detected by western blotting with a general phosphotyrosine antibody (4G10, Millipore) 
or a pY926-specific antibody (Santa Cruz).  The membranes were washed three times in 
TBST and incubated with the appropriate secondary antibody at room temperature for 
one hour (1:5000 α-rabbit (pTyr) and α-goat (p-Y926)).  Proteins were visualized using 
electrochemiluminescence (ECL) reagent (Pearce).   
Mass Spectrometry of Phosphorylated FAT: FTICR 
 The site of phosphorylation was verified by microelectrospray fourier transform 
ion cyclotron resonance mass spectrometry (µESI-FTICR-MS) by Dr. Li Zhou in the 
laboratory of Dr. Xian Chen.  Spectra were acquired on a hybrid Qe-FTICR mass 
spectrometer equipped with a 12.0 Tesla actively shielded magnet (Apex Qe-FTICR-MS, 
12.0 T AS, Bruker Daltonics, Billerica, MA, USA) and an Apollo II µESI source. The 
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voltages on the µESI spray capillary, spray shield, capillary exit, deflector, ion funnel and 
skimmer were set at +4.2 kV, +3.6 kV, +340 V, +310 V, +185 V, and +25 V, 
respectively. The temperature of the µESI source was maintained at 180°C. Desolvation 
was carried out by using a nebulization gas flow (2.0 bar) and a countercurrent drying gas 
flow (4.0 L second-1). cFAT samples were prepared by resuspending the lyophilized 
proteins in a mixture of acetonitrile/water/acetic acid (49.0:49.0:2.0 v/v/v) at a 
concentration of ~0.1 µg µL-1, directly infused with a syringe pump (Harvard Apparatus, 
Holliston, MA, USA) and a 100-µL syringe (Hamilton, Reno, NV, USA), and 
electrosprayed at an infusion flow rate of 90 µL hour-1. Before transfer, ion packets were 
accumulated inside the collision cell for a duration of 0.5 second.  One hundred MS scans 
per spectrum were acquired in the ICR cell with a resolution of 580,000 at m/z 400 Da. 
FTICR-electron capture dissociation (ECD) MS/MS was employed to fragment 
modified cFAT. Precursor ions were isolated with a quadrupole (Q1) and directly 
subjected to the ICR cell.  The isolation window width was 2.0 Da. Before transfer, ion 
packets were accumulated inside the collision cell for a duration of 1.0 seconds. Low 
energy electrons were generated by the heated hollow dispenser cathode with a bias 
voltage of -2.5 V. The ECD lens voltage was set at +15.0 V. The electrons produced by 
the hollow dispenser cathode (operated at 1.7 A) were pulsed into the ICR cell with a 
length of 3.0 ms, which led to fragmentation of the ions that were already trapped in the 
ICR cell. One hundred MS/MS scans per spectrum were acquired with a resolution of 
580,000 at m/z 400 Da. 
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Mass Spectrometry of Phosphorylated FAT: LC/MS 
 The site of phosphorylation was further verified by a bottom-up approach by 
LC/MS analysis of trypsin digest of the phosphorylation reaction by Dr. Harsha 
Gunawardena in the lab of Dr. Xian Chen.  After overnight incubation with Src, samples 
were desalted using PepClean C18 spin columns (Pierce, Rockford, IL) according to the 
manufacturer’s directions and re-suspended in an aqueous solution of 0.1% formic acid.  
Most of the samples were analyzed via reverse phase LC-MS/MS using a 2D-nanoLC 
ultra system (Eksigent Inc, Dublin, CA) coupled to an LTQ-Orbitrap XL system with 
electron transfer dissociation (ETD) (Thermo Scientific, San Jose, CA).  The Eksigent 
system was configured to trap and elute peptides in 1D mode of operation via a 
sandwiched injection of sample. Trapping was performed on a 3-cm long 100-µm i.d. 
C18 column whereas elution was performed on a 15-cm long 75-µm i.d., 5 µm, 300 Å 
particle ProteoPep II integraFrit C18 column (New Objective Inc, Woburn, MA). 
 Analytical separation of all the tryptic peptides was achieved with a linear 
gradient of 2-40% buffer B (0.1% formic acid in acetonitrile) over 70 min at a 200 
nL/min flow rate, where buffer A is 0.1% formic acid in an aqueous solution.  
Mass spectrometric data acquisition was performed in a data-dependent manner 
on a hybrid LTQ-Orbitrap mass spectrometer. A full scan mass analysis on an Orbitrap 
(externally calibrated to a mass accuracy of < 1 ppm and a resolution of 60,000) was 
followed by intensity dependent MS/MS of the top six most abundant peptide ions in the 
linear ion trap. Collision activated dissociation (CAD)-MS/MS and ETD-MS/MS were 
used as complimentary methods to dissociate peptides. All CAD-MS/MS spectra were 
obtained for peptide ions that were subjected to 30 ms resonance activation at a 
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normalized collision energy of 35 eV in the presence of He bath gas atoms at a pressure 
of 1 mTorr. All ETD-MS/MS spectra were obtained by performing an ion/ion reaction 
between peptide cations and fluoranthene anions mutually stored for 100 ms within a 
linear ion trap. The MS/MS acquisition of a precursor m/z was repeated for a 30 sec 
duration and subsequently excluded for 60 sec. Monoisotopic precursor ion selection and 
charge state screening was enabled to trigger data-dependent MS/MS scans. A few 
neutral H3PO4 loss dependent CAD-MS3 experiments and targeted peptide CAD-MS/MS 
experiments were also performed. 
 Mass spectra were processed, and peptide identification was performed using 
Mascot (Matrix Science Inc.) and Sequest (Thermo-Fisher Scientific) search algorithms 
against a human-IPI database (V3.63). Peptides were confidently identified using a 
target-decoy approach with a false discovery rate (FDR) of 1%. A precursor ion mass 
tolerance of 100 ppm and a product ion mass tolerance of 0.5 Da were used during the 
search with a maximum of two missed trypsin cleavages. Variable modifications included 
methionine oxidation and phosphorylation at serine, threonine, and tyrosine residues. The 
Ascore algorithm was used to confidently localize the phosphorylation site on the 
peptide.  
Peptide quantitation 
 Quantitation of site-specific phosphorylation in the full-length FAT domain was 
performed on the peptides that contained the two identified phosphorylation sites of full-
length FAT (pY-926 and pY-1008) via standard calibration.  Four phosphopeptides 
containing a 13C-labeled valine residue were synthesized to be used as internal standards 
by Dr. Krzysztof Krajewski in the laboratory of Dr. Brian Strahl at UNC-CH.  The 
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sequences of the peptides are as follows: SNDKV(p926Y)ENVTGL(V13C5)K-OH, 
V(p926Y)ENVTGL(V13C5)K-OH, LAQQ(p1008Y)(V13C5)MTSLQQEYK-OH, and 
MKLAQQ(p1008Y)(V13C5)MTSLQQEYK-OH.  The standardization was performed 
using a minimum of three-to-four standard concentrations (0.1, 0.2, 1, and 2 µg/mL) of 
the respective heavy stable isotope-labeled standard peptide.  The raw peaks were 
processed, and extracted ion chromatograms (XIC) were generated from the full-scan MS 
using Xcalibur software. Peptide peaks of interests were normalized by their stable 
isotope-labeled heavy internal standard counterpart using an in-house Perl script.  The 
integration of each analyte data point was performed using the Genesis algorithm 
(Thermo-Fisher Scientific, San Jose, CA).  All deviations in retention times were 
corrected by peak alignment. The accuracy of the peak area ratios were validated by 
acquiring multiple chromatographic runs with the linear gradients described above.  
Label-free absolute quantitation was based on the relative peak area of the identified 
phosphopeptide and corresponding phosphopeptide heavy internal standard.  A standard 
curve was generated by plotting the log of the normalized peak area (area of analyte/area 
of standard) versus the standard concentration.  The curves were fit by linear regression 
in Excel; the x-intercept of the fit represents the analyte concentration.  Both 3+ and 2+ 
charge states were quantified using these standard curves.   
 Quantification of the phosphorylation of the synthetic peptides as a function of pH 
was performed as described above except a single-point standard calibration was 
performed (0.5 µg/mL of heavy internal standard).  Phosphorylation reactions of the 
peptide containing Y926 were diluted 100 fold before analysis by MS whereas reactions 
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of the peptide containing Y1008 were diluted 4 fold before analysis by MS so that the 
signal was in an appropriate dynamic range for quantitation. 
Circular Dichroism 
 The CD experiments as a function of pH were conducted by Dr. Kirk Prutzman, a 
graduate student in the laboratory of Dr. Sharon Campbell at UNC-CH.  The FAT 
domain was exchanged into a degassed phosphate buffer (10 mM K2-HPO4, 0.01% 
NaN3) at pH 5.0, 5.5, 6.0, 6.5, 7.0, 7.5 and concentrated to 0.145 mg/mL.  Far –UV CD 
spectra (185-260 nm) were collected at 25°C on an Applied Photophysics Pistar-180 
spectropolarimeter at the UNC Macromolecular Interactions Facility.  Thermal 
denaturation studies were conducted by monitoring the ellipticity at 221 nm over a 
temperature range of 25 to 95°C at increments of 0.5°C.  Data points were collected after 
the temperature was constant (± 0.2°C) for 30 sec.  After each thermal denaturation run, 
the temperature was reduced to 25°C for 15 min, and a far-UV spectrum was collected to 
verify that the FAT domain had refolded.  After the far-UV spectrum was collected, a 
second thermal denaturation spectrum was collected and compared to the first spectrum 
to determine whether the thermal denaturation process was reversible. 
 Data analysis was conducted with the assumption that only populations of folded 
and unfolded species were being monitored and that any other species were not populated 
to any significant extent.  The denaturation curves were first corrected for baseline and 
then fit to a four variable sigmoidal curve in SigmaPlot.  The fit solves for the following 
variables: maximum, minimum, midpoint (Tm), and slope.  The data were normalized 
from 0 to1 by the following equation:  normalized value = (measured value – 
minimum)/(maximum – minimum). 
   
 
 
65 
NMR Spectroscopy 
 The FAT domain was expressed and purified as described above, except that cells 
were grown in M9 minimal media supplemented with 1 g/mL 15NH4 Cl and 10 g/L 12C 
glucose or 2 g/L 13C glucose for double-labeled samples.  
The purified FAT domain was exchanged into NMR buffer (25 mM Tris maleate 
pH 5.5, 6.0, 6.5, 7.0, or 7.5, 150 mM NaCl, 10% D2O, 0.01% NaN3) either by dialysis 
(MW cutoff 6,000-8,000 Da) or by an Amicon filtration device (MW cutoff 10,000 Da).  
Samples were concentrated by an Amicon filtration device (MW cutoff 10,000 Da).  1H-
5N 2D HSQC spectra as a function of pH and a simultaneous 3D 13C/15N-NOESY [83, 
84] at pH 6.0 and 7.5 were collected on a Varian INOVA 800 MHz spectrometer at 37°C.  
While temperature changes in some buffered solutions can affect the pH, we used a tris-
maleate buffer, which is relatively insensitive to temperature changes.  The spectra were 
referenced to each other using peaks associated with the glycine linker.  The backbone 
had been previously assigned at pH 6.0 and pH 7.5 by Dr. Kirk Prutzman, a graduate 
student in the laboratory of Dr. Sharon Campbell at UNC-CH.  The data were processed 
with NMRPipe [85] and analyzed with NMRView [86].   
15N Backbone Relaxation Dynamics of the FAT Domain as a Function of pH 
 T1, T2, and HetNOE spectra were collected on a 0.4 mM sample of 15N 
uniformly-labeled FAT domain on a Varian INOVA 600 MHz spectrometer at 37°C at 
pH 6.0 and pH 7.5.  Prior to data collection, the temperature was calibrated using a 100% 
methanol standard sample.  R1 and R2 relaxation rates were sampled with nine time 
points, three of which were collected in duplicate to estimate error.  Delay values of 48, 
136, 250, 385, 540, 708, 892, 1000, and 1300 ms were used for T1 experiments and 7, 15, 
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23, 39, 62, 78, 93, 109, and 125 ms were used for T2 experiments.  Two experiments 
comprising the 1H-15N NOE were acquired in an interleaved fashioned with a recycle 
delay ~ 5 sec.  For T1 and T2 analyses, the intensities of resolved amide peaks were fit to 
a single exponential decay using in-house programs provide by the laboratory of Andrew 
Lee (UNC-CH).  For analysis of the HetNOE data, the difference in intensity between the 
irradiated and non-irradiated spectra was determined using in-house programs provided 
by the laboratory of Andrew Lee (UNC-CH). 
 T1, T2, and HetNOE data were used to evaluate motions on the ps-ns timescale 
using the model-free formalism.  The isotropic rotational correlation times were 
determined using the approach described by Dellwo and Wand [87].  Backbone 
relaxation rates to fit to one- or two-parameter model-free models (S2, S2 + τe, or S2 + 
Rex) using an in-house program provided from the laboratory of Andrew Lee (UNC-CH) 
[88, 89].  The values used for the effective N-H bond distance and 15N chemical shift 
anisotropy were 1.02 Å and -170 ppm, respectively.  Akaike’s information criterion was 
used to select which model best describes the motion. 
Residual Dipolar Couplings 
 Pf1 phage (Asla Biotech) was added to a sample of 0.4 mM 15N-labeled FAT (in 
NMR buffer at pH 6.0 or pH 7.5) at a final concentration of 7.5 mg/mL.  1H-15N HSQC 
spectra were collected with and without Pf1 phage.  No significant changes in chemical 
shift were observed upon the addition of phage, indicating that the phage does not 
interact with the FAT domain.  1H-15N IPAP HSQC spectra [90] were collected on a 
Varian INOVA 700-MHz spectrometer with and without phage to measure the 1HN-15N 
residual dipolar coupling constant.  Two separate datasets were collected at pH 6.0, and 
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two datasets were collected at pH 7.5.  The data were processed with NMRPipe [85] and 
visualized with NMRView [86].  Peaks were picked manually.  We were able to measure 
47 dipolar coupling constants out of a possible 138 (146 residues minus 8 prolines) that 
were common between the pH 6.0 and pH 7.5 datasets.  The correlation between the 
RDC measurements was evaluated using the software Prism 5 (Graphpad). 
CLEANEX  
 CLEANEX-PM [77] spectra were collected on a Varian INOVA 600-MHz 
spectrometer at 37°C on a sample of 15N-labeled FAT domain at pH 6.0, 6.5, 7.0, and pH 
7.5 with a delay period of 0, 10, 20, 30 and 55 ms.  The data were processed by 
NMRPipe [85] and analyzed in NMRView [86].   
  
  
 
Chapter 3 
Characterization of Y926 Mutants of the FAT Domain 
Introduction  
 Focal adhesion kinase (FAK) is a nonreceptor tyrosine kinase that localizes to 
focal adhesions upon integrin activation.  FAK consists of an N-terminal FERM (4.1 
protein, ezrin, radixin, moesin) domain, a central kinase domain, and a C-terminal focal 
adhesion targeting (FAT) domain.  The FAT domain is responsible for proper 
localization and subsequent activation of FAK at least partially via its interaction with 
paxillin.  Also, phosphorylation of Y926 in the FAT domain has been implicated in 
promoting delocalization of FAK from focal adhesions and focal adhesion turnover and 
in linking FAK to the mitogen-activated protein kinase (MAPK) pathway, thus promoting 
angiogenesis and cell migration [19].  The focus of this study is on investigating various 
Y926 mutants of the FAT domain.    
 Phosphorylation of Y926 in the FAT domain has been linked to angiogenesis [19] 
and tumor invasion and metastasis [47].  In these studies, the role of phosphorylation was 
probed by mutating Y926 to a nonphosphorylatable mutant, namely Y926F.  Kaneda et 
al. demonstrated that a FAK Y926F mutant decreased migration and invasion in vitro and 
decreased metastasis in vivo [47].  However, they also reported that FAK Y926F is 
deficient in paxillin binding compared to wild type.  There are two paxillin binding sites 
in the FAT domain.  One site is located in a hydrophobic pocket between helices-1 and -4 
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whereas the other site is located between helices-2 and -3.  While the integrity of both 
sites is important for maximal FAK activation, the 1,4 site is more important for 
localization of FAK to focal adhesions than the 2,3 binding site [39].  Because Y926 is in 
helix-1, mutation of this site would be expected to disrupt the 1,4 paxillin binding site.  It 
has been shown that the Y926F mutant does localize to focal adhesions; however, these 
studies were not done quantitatively [19], and it is possible that the Y926F mutant 
reaches focal adhesions via an alternate paxillin-independent pathway [39].  Even if the 
Y926F mutant is successful at reaching focal adhesions, if it does so by using a secondary 
pathway, then one would expect a change in FAK/paxillin-mediated signaling pathways 
because paxillin is a substrate of FAK.  Therefore, impairment of FAT/paxillin 
interactions may lead to decreased phosphorylation of paxillin, which could lead to 
changes in paxillin-mediated signaling pathways.  Therefore, it is difficult to interpret in 
vivo data that rely on the Y926F mutant because it is difficult to distinguish whether 
effects of the mutation are due to a loss of phosphorylation at Y926 or a decrease in 
FAT/paxillin interactions.   
 While not as common, phosphomimetic mutants of the FAT domain have also 
been studied to investigate how phosphorylation at Y926 might alter the structure or 
dynamics of the FAT domain.  Zhou et al. conducted NMR-based hydrogen exchange 
studies as a function of denaturant to study the folding mechanism of Y926E and detected 
an intermediate state in which helix-1 is less structured [51].  This state is similar to the 
intermediate detected in our lab in wild type FAT using hydrogen exchange-directed 
discrete molecular dynamics (DMD) [50].  However, it is unclear whether introducing a 
negative charge at position 926 with an aspartate mutation affects the probability of the 
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intermediate state because no studies were performed with both the wild type FAT 
domain and the phosphomimetic mutant. 
 Because the Y926F mutant affects paxillin binding and therefore may affect FAK 
localization and signaling, we characterized this mutant in vitro to see if the mutation 
alters the structure of the FAT domain, thus altering paxillin binding.  Furthermore, 
because the Y926F mutant is known to be deficient in paxillin binding, we made a 
Y926A and Y926N mutant to determine whether a different mutation at Y926 would 
retain paxillin binding while still acting as a non-phophorylatable mutant, thus 
simplifying the analysis of in vivo studies.  We also characterized the Y926D and Y926E 
phosphomimetic mutants to investigate how phosphorylation might affect the structure 
and function of the FAT domain. 
 We investigated the structural properties of the Y926 mutants described above 
(Y926F, Y926A, Y926N, Y926D, and Y926E) by circular dichroism (CD) and NMR and 
analyzed their ability to bind paxillin by fluorescence polarization and pull-down assays.  
The CD experiments revealed that all of the mutants retained helical content and that the 
non-phosphorylatable mutants Y926F and Y926A had similar stability to wild type 
whereas the nonphosphorylatable mutant Y926N and the phosphomimetic mutants 
Y926D and Y926E were less stable than wild type.  Because we had evidence that the 
stability of the FAT domain is sensitive to pH (see pH chapter), we evaluated the stability 
of the Y926 mutants at pH 6.0 and pH 7.5.  The nonphosphorylatable mutants Y926F, 
Y926A, and Y926N had a similar sensitivity to pH as wild type with regard to stability 
whereas the stability of the phosphomimetic mutants Y926D and Y926E was less 
sensitive to pH than wild type.  The paxillin binding experiments revealed that none of 
   
 
 
71 
the mutants were able to bind to paxillin as well as wild type, suggesting that Y926 may 
be involved in key interactions between FAT and paxillin.  Therefore, it does not appear 
that there is an ideal nonphosphorylatable mutant of Y926 that can retain paxillin 
binding. 
Results/Discussion 
Expression of Y926 FAT Mutants 
 We used site-directed mutagenesis to mutate Y926 in the FAT domain to 
phenylalanine, alanine, asparagine, serine, aspartate, or glutamate.  We were not able to 
express or purify the serine mutant.  The other mutants, however, expressed and purified 
similarly to wild type and were conducive to biophysical studies.   
Circular Dichroism of Y926 Mutants 
 We first investigated whether mutation at Y926 affected the secondary structure 
of the FAT domain by CD.  Analysis of secondary structure by CD indicates that each 
mutant is helical, similar to wild type (data not shown).  We also analyzed the stability of 
these mutants by CD.  We collected CD melting curves at pH 6.0 and pH 7.5 because we 
have evidence that the stability of the wild type FAT domain is sensitive to pH (see pH 
chapter).  The melting curves of the Y926 mutants at pH 6.0 and 7.5 are shown in Figure 
3.1.  The values of the melting temperatures for each mutant at the two pH values are 
shown in Table 3.1.  
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 The nonphosphorylatable mutants Y926F and Y926A have similar melting curve 
profiles at both pH 6.0 and pH 7.5 and show a similar sensitivity to pH compared to wild 
type, with a change in about 12°C between pH 6.0 and pH 7.5.  However, the  
A. 
B. 
Figure 3.1: Thermal Denaturation of Y926 Mutants 
A. Thermal denaturation melting profiles at pH 6.0 and B. at pH 7.5 of Y926F (green), 
wild type FAT (black), Y926A (purple), Y926E (blue), Y926D (red), and Y926N (pink). 
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nonphosphorylatable mutant Y926N and the phosphomimetic mutants (Y926D and 
Y926E) are less stable than wild type FAT at both pH 6.0 and pH 7.5.  While the Y926N 
mutant has a similar sensitivity to pH as wild type, the Y926D and Y926E mutants are 
less sensitive to pH, with a change in about 7°C between pH 6.0 and pH 7.5.  Therefore, 
introducing a negative charge at Y926 destabilizes the FAT domain and seems to 
partially counteract the observed pH sensitivity.  Based on these data, one might 
speculate that if the FAT domain is regulated by pH in vivo, then upon phosphorylation, 
it is less sensitive to changes in pH.     
 
 
1H-15N HSQC Spectra of Y926 Mutants  
 To better ascertain whether various mutations at Y926 affect the structure of the 
FAT domain, we collected 1H-15N HSQC spectra on uniformly 15N-labeled FAT 
constructs.  Figure 3.2 shows an overlay of the wild type spectrum (black) and the 
corresponding FAT mutant spectrum (color).  There are considerable chemical shift  
changes between the HSQC spectra of wild type FAT and the mutants.  These shifts are 
not localized to the site of mutation.  Rather, chemical shift changes are seen throughout  
Table 3.1: Melting temperatures of Y926 mutants of the FAT domain as a 
function of pH 
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Figure 3.2: 1H-15N HSQC Spectra of the Y926 Mutants 
Overlay of the 1H-15N HSQC spectra of wild type FAT with A. Y926F, B. Y926A, C. 
Y926N, D. Y926D, and E. Y926E.  F. Overlay of the 1H-15N HSQC spectra of Y926D 
(blue) and Y926E (red).  Data were collected at pH 6.0 at 37°C.  The spectra were 
referenced by aligning the peaks of the glycine linker (in box in A.)     
1H ppm 1H ppm 
15N 
ppm 
15N 
ppm 
15N 
ppm 
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the 3D structure of the protein.  Interestingly, there are also considerable chemical shift 
differences between the Y926D and Y926E spectra (Figure 3.2F).  This is rather 
surprising because the Y926D and Y926E mutants differ by a single methylene group.  
Qualitative analysis of the Y926D and Y926E spectra suggests that the Y926D spectra is 
more similar to that of wild type FAT than the Y926E spectrum, perhaps suggesting that 
Y926E is a better phosphomimetic that Y926D, which is consistent with the fact that 
glutamate has a longer side chain than aspartate, which would be expected to more 
closely resemble the size of the tyrosine side chain.   
 A change in chemical shift suggests that the electrochemical environment of that 
residue has changed.  It is therefore difficult to determine if changes in chemical shift are 
due to structural changes in the FAT domain or simply slight changes in the local 
environment that may propagate from the site of mutation.  To better determine whether 
mutations at Y926 cause structural changes in the FAT domain, it will first be necessary 
to assign the HSQC spectra of the mutants.  While a large number of the peaks can 
probably be assigned based on comparison with the wild type spectrum, the differences 
between the spectra are so pervasive that it is necessary to collect additional three-
dimensional NMR data on the mutants to unequivocally assign the spectra.  Once that is 
accomplished, further experiments, such as RDCs, will help to clarify whether there is a 
structural change.  
Paxillin Binding of the Y926 Mutants  
 We also examined these mutants’ ability to bind paxillin in vitro.  We first pulled 
down endogenous full-length paxillin from REF52 lysates using GST-FAT and blotted 
for paxillin.  Figure 3.3 shows the results of a pull-down experiment.  As expected, wild 
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type FAT shows robust paxillin binding.  Similar to the results of Kaneda et al., we 
observed that Y926F does not bind to paxillin as well as wild type; however, among the 
Y926 mutants, the paxillin binding to the Y926F mutant is the most similar to that of 
wild type FAT.  Some paxillin binding is observed with Y926A whereas paxillin binding 
is undetectable with the Y926N, Y926E, and Y926D mutants.  These data are consistent 
with the thermal denaturation data in which the stabilities of the Y926F and Y926A 
mutants were more similar to wild type whereas the Y926D, Y926E, and Y926N mutants 
were significantly less stable than wild type. 
 The fact that Y926D and Y926E do not show any paxillin binding suggests that 
phosphorylation at Y926 may also disrupt paxillin binding.  It has been speculated that 
phosphorylation at Y926 and paxillin binding are mutually exclusive because the paxillin 
binding site includes Y926; however, it has not been directly shown that this is the case.  
The fact that every mutation we have made so far at this site impairs paxillin binding 
suggests that Y926 may play a critical role in paxillin binding. 
 To gain more quantitative information, we also analyzed paxillin binding to the 
FAT domain by fluorescence polarization.  We used a 28-mer peptide conjugated to the 
fluorophore 5-carboxyfluorescein (5-FAM) designed to mimic the LD2 motif of paxillin, 
which has been shown to bind to the FAT domain at two sites, in a hydrophobic groove 
between helices-1 and -4 and between helices-2 and -3 [43].  The groove between 
Figure 3.3: Paxillin Pull-
Downs of the Y926 Mutants 
Endogenous paxillin was pulled 
down from REF52 cell lysates 
with the indicated amount of 
immobilized GST-FAT 
constructs.  Paxillin and FAT 
were detected by Western blot. 
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helices-1 and -4 contains Y926, and a perturbation at this site, for example mutation of 
Y926, might be expected to disrupt paxillin binding.  Figure 3.4 shows representative 
binding curves for wild type FAT and the Y926 mutants, and the Kd values are shown in 
Table 3.2.  Wild type FAT has a Kd of approximately 7 µM, which is consistent with 
what has been previously observed by isothermal titration calorimetry (ITC) [43].  
Similar to the pull-down experiments, none of the mutants were able to bind paxillin as 
well as the wild type protein.  The Kd values for the mutants increased by about a factor 
of two compared wild type.  It is somewhat difficult to compare these Kd values as they 
were fit assuming one binding site, and LD2 is known to bind to two sites on the FAT 
domain [40, 43].  However, we were hesitant to fit the binding curves of the Y926 
mutants to a two-site model because we suspected that mutation of Y926 could eliminate 
binding to the 1,4 binding site.  Therefore, the Kd values in Table 3.2 should be 
interpreted as apparent binding affinities.  Analysis by ITC would allow us to determine 
the stoichiometry of the binding interacting and to more appropriately fit the fluorescence 
polarization data.     
 It is interesting to note that paxillin binding to Y926N, Y926E, and Y926D was 
not observable in the pull-down assays whereas in the fluorescence polarization assay, 
the Kd only increases by a factor of two.  As mentioned above, we are using a short (27-
mer) peptide of paxillin in the fluorescence polarization assay, and, in the complex of this 
peptide and the FAT domain [43], Y926 is near the N-terminus of the peptide.  Therefore, 
in the context of full-length paxillin, Y926 may be involved in interactions that are not 
possible in the context of the paxillin peptide.  Thus, mutations of Y926 may not have as 
profound of an effect on binding the paxillin peptide as binding to full-length paxillin.   
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Therefore, future studies should include a longer paxillin peptide construct to ensure that 
any interaction between position 926 and paxillin is taken into account.  Also of interest 
is that whereas the Y926F mutant showed the highest paxillin binding among the Y926 
mutants via the pull-down assay, it showed the weakest binding in the fluorescence 
Figure 3.4: Binding of the Y926 Mutants to the LD2 Peptide: 
Binding of the FAT domain to the LD2 paxillin peptide conjugated to the fluorophore 5-FAM was 
detected by fluorescence polarization.  Each data point represents the average of nine measurements.  
Experiments were conducted at room termperature. 
Table 3.2 Binding Affinities of Y926 
Mutants to the LD2 peptide 
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polarization assay.  Again, this discrepancy is probably due to the fact that, in the pull-
down assays, the FAT domain is binding to full-length paxillin whereas in the 
fluorescence polarization assays the FAT domain is binding to a short peptide.  This 
discrepancy further highlights the need to test paxillin binding in the context of a longer 
paxillin peptide that is able to interact with Y926.   
Conclusion 
 Phosphorylation of Y926 in the FAT domain of FAK is important for FAK 
signaling and has been shown to play a role in angiogenesis [19] and tumor invasion and 
metastasis [47].  In these studies, the effects of phosphorylation were probed by mutating 
Y926 to a non-phosphorylatable residue, namely phenylalanine.  However, the Y926F 
mutant was also shown to be deficient in paxillin binding [47], which is important for 
proper localization and activation of FAK [34, 91].  Therefore, the results of in vivo 
experiments that use the Y926F mutant are difficult to interpret as they may be due to 
either defects in phosphorylation or paxillin binding. 
 In this study, we characterized the Y926F mutant of the FAT domain as well as 
two additional non-phosphorylatable mutants (Y926A and Y926N) and two 
phophomimetic mutants (Y926D and Y926E) to determine whether mutations at this site 
disrupt the structure of the FAT domain and to identify a mutation at this site that does 
not disrupt paxillin binding.  Analysis of these mutants by thermal denaturation reveals 
that the Y926F and Y926A mutants have similar stability as the wild type FAT domain 
whereas the Y926N mutant is less stable than wild type.  Y926 is located in the first turn 
of helix-1 in the FAT domain and is partially exposed to the solvent.  It is unclear from 
the structure why mutation to asparagine would have such a profound effect on stability.  
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Analysis of these mutants by NMR reveals that widespread changes in chemical shift are 
present in the 1H-15N HSQC spectra of all the mutants compared to wild type.  It is 
difficult to tell from the HSQC spectrum alone what type, if any, of structural change 
may be occurring upon mutation of Y926.  If these analyses are to be taken further, these 
spectra must first be assigned using three-dimensional NMR techniques.  Once that is 
accomplished, other experiments such as RDCs can better elucidate if a change in 
structure occurs upon mutation of Y926. 
 Whether mutation of Y926 causes a structural change in the FAT domain, it is 
known to have functional consequences, i.e., disruption of paxillin binding.  We observed 
by pull-down assays and fluorescence polarization that the Y926F mutant does not bind 
to paxillin as well as wild type, which is consistent with previous reports [47].  Mutation 
of Y926 to alanine or aspargine did not rescue this deficiency in paxillin binding.  In fact, 
of the mutants we tested, Y926F showed the highest paxillin binding.  Therefore, it 
appears that there is not an ideal nonphosphorylatable mutant of the FAT domain that 
retains wild type levels of paxillin binding and that Y926F seems to be the best mutant 
available.  However, because it does have a decreased affinity for paxillin compared to 
wild type FAT, the caveats of in vivo studies with this mutant should be taken into 
consideration when interpreting results from these studies. 
 We were unable to detect paxillin binding to the phosphomimetic mutants, Y926E 
and Y926D, by paxillin pull-downs.  These mutants were made to mimic the negative 
charge of a phosphate group.  Addition of a negative charge at Y926 destabilized the 
FAT domain and decreased its sensitivity to pH.  The destabilization could be due to the 
fact that the side chain of D1040, located in helix-4 of the FAT domain, points toward 
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Y926.  In the crystal structure of the FAT domain, D1040 is involved in a salt bridge with 
R920 [48], which is one of the interactions that tethers helix-1 to helix-4.  In the NMR 
structure of the FAT domain [49], this salt bridge is not apparent.  It is possible that the 
addition of a negative charge at Y926 could either interfere with this interaction or is 
simply destabilizing because of the introduction of negative charge near a negatively-
charged residue (D1040).  It is interesting to speculate that phosphorylation at Y926 may 
have a similar effect, which could have consequences on how phospho-Y926 is 
recognized by the SH2 domain of Grb2.  It is difficult to speculate on the mechanism for 
the decrease in sensitivity to pH observed in the Y926D and Y926E mutants as we do not 
currently know what is causing this pH sensitivity.  We have mutated D1040 to alanine 
and do not see a change in the pH sensitivity of the protein (see Chapter 2).           
Methods  
Mutagenesis 
The construct expressing the GST-wtFAT domain fusion protein has been 
described elsewhere [49].  The Quikchange mutagenesis protocol (Stratagene) was used 
to incorporate point mutations into position 926.  The following primers were used to 
make the desired mutants (bold indicates site of mutation): 
Y926F 
5’ CGC TCC AAT GAC AAA GTC TTT GAG AAT GTA AAC GGG CTG 3’ 
Y926D 
5’ CGC TCC AAT GAC AAA GTC GAT GAG AAT GTA AAC GGG CTG 3’ 
Y926E 
5’ CGC TCC AAT GAC AAA GTC GAA GAG AAT GTA AAC GGG CTG 3’ 
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Y926A 
5’ CGC TCC AAT GAC AAA GTC GCG GAG AAT GTA AAC GGG CTG 3’ 
Y926S 
5’ CGC TCC AAT GAC AAA GTC TCT GAG AAT GTA AAC GGG CTG 3’ and 
5’ CGC TCC AAT GAC AAA GTC TCT GAG AAT GTA AAC GGG CTG GTG 3’ 
Y926N 
5’ CGC TCC AAT GAC AAA GTC AAC GAG AAT GTA AAC GGG CTG 3’ 
 Quikchange reactions were digested with DpnI at 37°C to remove any template 
DNA and transformed into DH5α E. coli cells.  Single colonies were chosen and 
incubated in LB-Amp overnight, and plasmid DNA was purified using the Qiagen 
Miniprep kit.  The mutation was verified by sequencing at the UNC-CH Genome 
Analysis Facility using the pGEX 5’ sequencing primer (5’ 
GGGCTGGCAAGCCACGTTTGGTG 3’). 
Expression and Purification of wild type and mutant FAT 
 The FAT domain construct used in these studies contains residues 920 to 1053 of 
chicken FAK plus a 12 amino acid N-terminal linker (bold): 
(GSPGISGGGGGIRSNDKVYENVTGLVKAVIEMSSKIQPAPPEEYVPMVKEVGL
ALRTLLATVDESLPVLPASTHREIEMAQKLLNSDLAELINKMKLAQQYVMTSLQ
QEYKKQMLTAAHALAVDAKNLLDVIDQARLKMISQSRPH).  The FAT domain 
was expressed as a GST fusion protein as previously described [49].  The pGEX-KG 
plasmid containing the GST-FAT sequence was transformed into BL21(DE3) E. coli 
cells for protein expression.  Bacteria were grown in LB-Amp at 37°C to an OD600 ~ 0.6.  
Expression was then induced by the addition of 0.5 mM IPTG, and cells were grown for a 
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further three to five hours before harvesting by centrifugation.  Cells were resuspended in 
lysis buffer (20 mM Tris pH 7.5, 10% glycerol, 10 mM DTT, 150 mM NaCl) and lysed 
by sonication (5 sec. on 5 sec. off for a total of one hour).  The lysate was centrifuged at 
15k rpm for 70 min. to remove insoluble cell debris.  The supernatant was added to 
glutathione-agarose (GSH) beads and incubated at 4°C overnight.  The beads were 
washed once with lysis buffer and two times with thrombin cleavage buffer (50 mM Tris 
pH 8.0, 150 mM NaCl, 2.5 mM CaCl2, 0.1% BME).  Typically, about 0.5 units/mL of 
thrombin were added to the beads to cleave the fusion protein.  The beads were incubated 
with thrombin at room temperature overnight and then washed three times with thrombin 
cleavage buffer.  The supernatants of these washes were combined, and thrombin activity 
was inhibited by the addition of p-aminobenzamidine agarose beads, which were 
subsequently removed by centrifugation.  The protein was dialyzed into S-column buffer 
A (25 mM NaPO4 pH 5.5, 0.01% NaN3) and purified by cation-exchange 
chromatography on a mono S column and eluted with a gradient of 0 – 1 M NaCl over 
200 mL.  The protease inhibitors PPACK (1 µM) and pefablock (0.5 mg/mL) were added 
to the purified protein to prevent degradation.  All mutants were purified in a similar 
manner. 
 Protein concentration was measured by diluting the protein in a final 
concentration of 6 M guanidinium hydrochloride and measuring the absorbance at 280 
nm.  The concentration was calculated using the calculated extinction coefficient at 280 
nm (5120 M-1cm-1 for wild type and 4470 M-1cm-1 for the mutants) from the ProtParam 
tool on the ExPASy proteomics server [80]. 
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Circular Dichroism 
 Purified protein was dialyzed into CD buffer (10 mM NaPO4) at the desired pH.  
Because Cl- ions interfere with the CD signal, the desired pH was acquired by combining 
10 mM Na2HPO4 and 10 mM NaH2PO4.  The proteins were concentrated using an 
Amicon filtration device (MWCO 10 kDa), and the concentration was adjusted to 50 µM.  
CD spectra were collected at the Macromolecular Interactions Facility at UNC-CH on a 
Chirascan spectrometer.  Wavelength scans were collected from 260 –180 nm with a 0.5 
nm step size.  Thermal denaturation was monitored at 222 nm from 25°C to 95°C with a 
ramp speed of 1°C/min and a tolerance of 0.2°C.  The data were normalized from 0 to 
100 and fit in Prism 5.0 to a sigmoidal curve with variable slope: y = minimum 
+(maximum-minimum)/(1+10log(Tm-x)-slope), where y is the normalized ellipticity, x is the 
temperature, Tm is the melting temperature, and slope is the Hill coefficient. 
NMR Spectroscopy 
 The wild type FAT domain and mutants were expressed and purified as described 
above, except that cells were grown in M9 minimal media supplemented with 1 g/mL 
15NH4 Cl.  
The purified FAT domain was exchanged into NMR buffer (25 mM tris maleate 
pH 6.0, 150 mM NaCl, 10% D2O, 0.01% NaN3) either by dialysis (MW cutoff 6,000-
8,000 Da) or by an Amicon filtration device (MW cutoff 10,000 Da).  Samples were 
concentrated by an Amicon filtration device (MW cutoff 10,000 Da).  1H-15N HSQC 
spectra were collected on either a Varian INOVA 500-, 600-, or 700-MHz spectrometer 
at 37°C.  The data were processed with NMRPipe [85] and analyzed with NMRView 
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[86].  The mutants were referenced to the wild type 1H-15N HSQC spectrum using the 
peaks of the glycine linker. 
Fluorescence Polarization 
 The FAT domain was dialyzed into 50 mM HEPES pH 7.0, 100 mM NaCl, 0.01% 
NaN3 and concentrated with an Amicon filtration device (MWCO 10 kDa).  The 
concentration was adjusted to 50 µM.  The LD2 peptide, which mimics the LD2 motif of 
paxillin (133MTSTSLGSNLSELDRLLLELNAVQHNP159) was synthesized with the 
fluorophore 5-carboxyfluorescein (5-FAM) conjugated to the N-terminus by Dr. 
Krzysztof Krajewski in the laboratory of Dr. Brian Strahl at UNC-CH.  The FAT domain 
was titrated into a quartz cuvette containing 1 mM of the LD2 peptide.  The polarization 
was measured one minute after addition of the FAT domain to allow the system to reach 
equilibrium.  Fluorescence polarization was collected on a Jobin Yvon Horiba 
Fluoromax-3 fluorimeter with dark value correction at room temperature.  The slit width 
was set to 2 nm; the excitation wavelength was 492 nm, and the emission wavelength was 
526 nm.  The integration time was 1.0 sec, and each datapoint is the average of nine 
measurements.  The data were fit using SigmaPlot.    
Paxillin Pull-Downs 
 Rat embryo fibroblasts (REF52) were grown in Dulbecco’s Eagle medium 
supplemented with 10% fetal bovine serum (FBS) and 0.1% antibiotic-antimyotic (PSF).  
Cells were placed on ice, washed with 1X phosphate buffered saline (PBS) and lysed in 
ice-cold RIPA buffer (150 mM NaCl, 50 mM Tris pH 7.6, 1% Triton X-100, 0.1% SDS, 
0.25% deoxycholate, 200 µM orthovanadate, 1 µg/mL aprotinin, 1 µg/mL leupeptin, 1 
   
 
 
86 
mM PMSF).  Lysates were centrifuged at 13,000 rpm at 4°C, and the supernatant was 
carefully collected and kept at -80°C until use.   
 GST-FAT fusion proteins were expressed and purified as described above.  
However, after incubation with GSH beads, the beads were washed three times with lysis 
buffer.  GST-FAT concentration was estimated by a BCA assay (Pierce).  The specified 
amount of immobilized GST-FAT was incubated with REF52 lysate for approximately 
two hours at 4°C.  To keep the background consistent, blank GSH beads were added to 
the reaction so that the total amount of GSH beads was constant.  After incubation, the 
beads were spun down and the supernatant removed.  The beads were washed three times 
with RIPA buffer and once with PBS.  Proteins were separated by SDS-PAGE and 
transferred to a polyvinylidene fluoride (PVDF) (Millipore) at approximately 85 V for 
one hour for western blotting analysis.  The membrane was blocked with 5% milk for one 
hour at room temperature and then incubated with anti-paxillin (BD Transduction 
Laboratories Catalog # 610051) or anti-FAK antibodies (BC4 [5, 91], provided by Dr. 
Michael Schaller) (1:1000 dilution, 5% milk) for either one hour at room temperature or 
overnight at 4°C.  After incubation with the primary antibody, the membrane was washed 
three times with TBST and incubated with the secondary antibody (anti-mouse IgG for 
paxillin and anti-rabbit IgG for FAK, 1:10000 dilution, 5% milk) for one hour at room 
temperature.  The membrane was then washed three times with TBST, and proteins were 
visualized via SuperSignal West Pico Chemiluminescent Substrate (Pierce) and 
visualized using Kodak BioMax film (Kodak).  For quantification of western blots, 
intensity values of bands were measured from three different repeats for each experiment 
using Image J software (NIH).  
  
 
CHAPTER 4 
FAT/TALIN INTERACTIONS 
Introduction 
 FAK is a 125-kDa protein that is involved in cell adhesion and migration.  FAK 
localizes to focal adhesions upon integrin activation and plays a key role in both focal 
adhesion assembly and disassembly.  Localization of FAK to focal adhesions is mediated 
by the C-terminal focal adhesion targeting (FAT) domain [37, 38].  While it seems that 
there are several mechanisms by which the FAT domain can direct proper localization of 
FAK, the major mechanism seems to be the interaction of the FAT domain with paxillin 
[34, 39].  However, secondary mechanisms of localization have been proposed as there 
are mutants of the FAT domain that do not bind to paxillin that still localize to focal 
adhesions, albeit less than wild type [39].      
 One possibility for a paxillin-independent mechanism of localization is the 
interaction between the FAT domain of FAK and talin.  Talin is a 270-kDa protein that 
consists of an N-terminal head domain and a C-terminal rod domain.  The head domain is 
made up of a FERM domain (4.1/ezrin/radixin/moesin), which contains an F1, F2, and F3 
lobe that mediates protein-protein interactions [92].  In particular, the F3 domain of talin 
binds to integrin tails whereas the rod domain of talin contains at least two actin binding 
sites.  In this way, talin provides a physical link between integrins and the actin 
cytoskeleton at sites of focal adhesions [92].  Observations that talin co-
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immunoprecipitates with FAK suggested an interaction between these two proteins in 
vivo [41, 42].  Furthermore, recombinant constructs of FAK were able to bind to 
immobilized talin that had been immunoprecipitated from SDS-denatured cell lysates to 
disrupt any talin/protein interactions that could mediate an indirect interaction with FAK, 
suggesting that the observed interaction between FAK and talin is indeed direct [41].  
Attempts to localize the talin binding site of FAK revealed that deletion of residues 965-
1012 of FAK, which are in the FAT domain, abrogate binding to talin, suggesting that 
talin binds to the FAT domain of FAK [41].  Interestingly, Pyk2, a close homolog of 
FAK that does not localize to focal adhesions does not bind to talin.  However, a chimeric 
protein containing the N-terminal domains of Pyk2 and the C-terminal domain of FAK is 
able to bind talin and localize to focal adhesions [42].  These data suggest that talin 
binding to the FAT domain of FAK may be involved in localization to focal adhesions 
and that the FAK/talin interaction could be one mechanism that differentiates the 
functions of FAK from those of Pyk2.  However, more recent studies have had 
difficulties detecting an interaction between FAK and talin [39], and a possible role for 
the FAK/talin interaction remains both controversial and elusive. 
 Unpublished data from the laboratory of Dr. David Schlaepfer at UCSD indicate 
that the FAT domain of FAK interacts with an F2F3 domain construct of talin, with the 
F3 domain containing the minimal necessary binding site.  Attempts to purify the talin 
F2F3 domain construct were unsuccessful.  Therefore, we tested whether we could detect 
an interaction in vitro between purified FAT and talin F3 domain constructs by gel 
filtration and NMR and were unable to detect an interaction under our conditions.  
   
 
 
89 
Results/Discussion 
Purification of Talin Constructs 
 Several talin constructs were provided by Dr. Christine Lawson in the laboratory 
of Dr. David Schlaepfer at UCSD.  First, two constructs containing the talin F2/F3 (206-
405) and F3 domains (311-405) in pGEX-4T1 plasmids were expressed and purified from 
E. coli.  While these proteins expressed well, they did not seem to be stable upon 
cleavage of the GST tag by thrombin.  Therefore, these constructs were not considered to 
be conducive to NMR analyses.  Next, a construct containing talin F2/F3 (209-400) in a 
pet28a vector was expressed and purified.  While this construct expressed and purified 
well, we were not able to concentrate it to the levels need for NMR analyses (~ 100-400 
µM), especially upon the addition of the FAT domain, as the protein precipitated out of 
solution.  Finally, a talin F3 construct (309-405) in a pet28a vector was acquired that 
remained soluble at micromolar concentrations when combined with the FAT domain. 
Gel Filtration of FAT/Talin 
 To determine whether the FAT domain interacts with the talin F3 domain in vitro, 
the two purified constructs were combined in a 1:1 ratio and run over an S75 column.  
Figure 4.1A shows an overlay of the traces from talin F3 alone, FAT alone, and FAT + 
talin F3.  As expected, the talin F3 domain (11 kD) elutes slightly later than the FAT 
domain (16 kD).  While the two individual proteins are not able to be resolved in the FAT 
+ talin trace, there is no peak that corresponds to a FAT/talin complex (27 kD).  Figure 
4.1B shows the Coomassie-stained gel of the fractions from the FAT/talin run.  The SDS-
PAGE gel indicates that the two proteins elute separately and, as expected from the FAT 
alone and talin alone runs, the talin F3 domain elutes slightly later than the FAT domain.  
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While we were unable to detect an interaction between the talin F3 domain and the FAT 
domain by gel filtration, this method is not capable of detecting weak interactions.  
Therefore, we decided to investigate a possible interaction by NMR because this method 
is capable of detecting weak interactions (kd ~ mM). 
HSQC Spectra of FAT/Talin 
 To further investigate 
whether we could detect a 
FAT/talin interaction in vitro, 
we combined 15N-labeled 
FAT with unlabeled talin.  
1H-15N HSQC spectra were 
collected under a variety of 
conditions: pH 6.0, 25°C 
with a 5-fold molar excess of 
talin; pH 6.0, 37°C with a 5-
fold molar excess of talin; pH 
7.5, 25°C with a 5-fold molar excess of talin; and pH 7.5, 25°C with a 10-fold molar 
excess of talin.  Because the sample precipitated out of solution at 37°C at pH 6.0, we did 
not attempt to collect data at 37°C for the pH 7.5 sample.  Figure 4.2 shows the overlay 
of the 1H-15N HSQC spectra of the FAT domain alone (black) and with 5:1 molar excess 
of talin F3 (red) at pH 6.0.  No changes in chemical shift are observed between the two 
spectra, indicating that the talin F3 domain does not interact with the FAT domain under 
Figure 4.1: Gel Filtration of FAT/Talin   
(A) Overlay of gel filtration chromatogram of FAT alone (blue, 
solid line), talin alone (red, dashed line), and FAT + talin 
(green, dotted line).  (B) Coomassie-stained gel of fractions 11-
14 showing the elutions profiles of the FAT + talin gel 
filtration run. 
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these conditions.  Similar results were observed for the other conditions described above 
(data not shown). 
 
Conclusion 
 The FAT domain of FAK has been shown to bind to talin in vivo via co-
immunoprecipitation; however, others have been unable to detect a direct interaction 
between talin and the FAT domain via several different methods [39].  In this paper, we 
investigated the interaction between the FAT domain of FAK and the F3 domain of talin.  
As described above, we had some difficulties finding a talin F3 or F2/F3 construct that 
was soluble at the concentrations necessary for NMR analyses.  In particular, 
precipitation of the talin constructs appeared to be exacerbated upon addition of the FAT 
domain, possibly indicating that an interaction is occurring in solution but that the 
complex is not stable under our experimental conditions.  No precipitation issues were 
Figure 4.2: 1H-15N 
HSQC of the FAT 
Domain with Talin: 
Overlay of the 1H-15N 
HSQC of 15N-labeled 
wild type FAT (black) 
and 15N-labeled wild 
type FAT with a 5-fold 
molar excess of 
unlabeled talin F3 
domain.  These spectra 
were collected at pH 
6.0 at 25°C.  The lack 
of changes in chemical 
shift upon the addition 
of the talin F3 domain 
indicates that there is 
no interaction between 
these two proteins. 
(ppm) 
(ppm) 
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encountered with the talin F3 (309-405) construct upon addition of the FAT domain, and 
we were unable to detect an interaction between these two domains by either gel filtration 
or NMR.  It is unclear whether our inability to detect a direct interaction between the 
FAT domain and the F3 domain of talin indicates that no so interaction exists or that the 
conditions we used were not conducive to FAT/talin binding.  It is possible that the F2 
domain of talin is necessary either for proper binding to the FAT domain or for proper 
folding of the F3 domain.  A recent crystal structure of the talin head domain containing 
the F0, F1, F2, and F3 domains revealed several interactions including salt bridges, 
hydrogen bonds, and hydrophobic interactions between the F2 and F3 domains [93].  As 
stated earlier in the text, we attempted to purify several F2F3 domain constructs; 
however, none of these constructs were amenable to NMR analyses.  However, an F2/F3 
domain construct of talin has been used in crystallographic studies in which 
concentrations of up to 250 µM were achieved [94].  If this complex remains soluble 
upon addition of the FAT domain, it will be interesting to see whether an interaction can 
be detected between the FAT domain and the F2F3 domains of talin.       
Methods 
Expression and Purification of the FAT Domain 
 The FAT domain construct used in these studies contains residues 920 to 1053 of 
chicken FAK plus a 12 amino acid N-terminal linker (bold): 
(GSPGISGGGGGIRSNDKVYENVTGLVKAVIEMSSKIQPAPPEEYVPMVKEVGL
ALRTLLATVDESLPVLPASTHREIEMAQKLLNSDLAELINKMKLAQQYVMTSLQ
QEYKKQMLTAAHALAVDAKNLLDVIDQARLKMISQSRPH).  The FAT domain 
was expressed as a GST fusion protein as previously described [49].  The pGEX-KG 
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plasmid containing the GST-FAT sequence was transformed into BL21(DE3) E. coli 
cells for protein expression.  Bacteria were grown in LB-Amp at 37°C to an OD600 ~ 0.6.  
Expression was then induced by the addition of 0.5 mM IPTG, and cells were grown for a 
further three to five hours before harvesting by centrifugation.  Cells were resuspended in 
lysis buffer (20 mM Tris pH 7.5, 10% glycerol, 10 mM DTT, 150 mM NaCl) and lysed 
by sonication (5 sec. on 5 sec. off for a total of one hour).  The lysate was centrifuged at 
15k rpm for 70 min. to remove insoluble cell debris.  The supernatant was added to 
glutathione-agarose (GSH) beads and incubated at 4°C overnight.  The beads were 
washed once with lysis buffer and two times with thrombin cleavage buffer (50 mM Tris 
pH 8.0, 150 mM NaCl, 2.5 mM CaCl2, 0.1% BME).  Typically, about 0.5 units/mL of 
thrombin were added to the beads to cleave the fusion protein.  The beads were incubated 
with thrombin at room temperature overnight and then washed three times with thrombin 
cleavage buffer.  The supernatants of these washes were combined, and thrombin activity 
was inhibited by the addition of p-aminobenzamidine agarose beads, which were 
subsequently removed by centrifugation.  The protein was dialyzed into S-column buffer 
A (25 mM NaPO4 pH 5.5, 0.01% NaN3) and purified by cation-exchange 
chromatography on a mono S column and eluted with a gradient of 0 – 1 M NaCl over 
200 mL.  The protease inhibitors PPACK (1 µM) and pefablock (0.5 mg/mL) were added 
to the purified protein to prevent proteolytic degradation.  
Expression and Purification of the Talin F3 Domain 
 Several talin constructs were provided by Dr. Christine Lawson in the laboratory 
of Dr. David Schlaepfer at UCSD: mouse talin F2/F3 (206-405) in a pGEX-4T1 vector, 
mouse talin F3 (311-405) in a pGEX-4T1 vector, chicken talin F2/F3 (209-400) in a 
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pet28a vector, and mouse talin F3 (309-405) in a pet28a vector.  While all of these 
constructs expressed well in E. coli, only the talin F3 (309-405) construct was amenable 
to purification and the concentrations needed for NMR analyses (~ 0.1 mM). 
 The talin F3 domain (309-405) was cloned into a pet28a vector by Dr. Christine 
Lawson in the laboratory of Dr. David Schlaepfer at UCSD.  The plasmid was 
transformed into E. coli BL21 cells for protein expression.  Cells were grown in LB-Kan 
to an OD600 ~ 0.6 at 37°C, at which time the temperature was reduced to 18°C for about 
an hour.  Protein expression was then induced by the addition of 0.25 mM ITPG, and the 
cells were incubated overnight at 18°C.  The cells were harvested by centrifugation, 
resuspended in lysis buffer (50 mM Tris pH 8.0, 500 mM NaCl, 5% glycerol, 5 mM 
imidazole), and lysed by sonication.  The lysate was cleared by centrifugation and 
applied to a Ni2+ affinity column that had been pre-equilibrated with lysis buffer.  The 
column was washed with two column volumes of lysis buffer followed by two column 
volumes of lysis buffer with 50 mM imidazole.  Protein was eluted with lysis buffer with 
300 mM imidazole.  Ten 5-mL fractions were collected, and the presence of the talin F3 
domain was verified by SDS-PAGE.  Fractions containing the F3 domain were combined 
and dialyzed against thrombin cleavage buffer (50 mM Tris pH 8.0, 150 mM NaCl, 2.5 
mM CaCl2, 0.1% BME) with 5-10 units of thrombin at room temperature overnight.  
Thrombin activity was inhibited by the addition of p-aminobenzamidine agarose beads, 
which were subsequently removed by centrifugation.  The protein was then loaded onto a 
mono-S column and eluted with a gradient of 150 – 1000 mM NaCl over 200 mL.  The 
presence and purity of the F3 domain was verified by SDS-PAGE. 
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Gel Filtration of the Talin F3 Domain 
 The talin F3 domain and wild type FAT domain were dialyzed into 25 mM Tris-
Maleate, pH 6.0, 150 mM NaCl, and 0.01% NaN3 overnight at 4°C.  The proteins were 
concentrated with an Amicon filtration device (MW cutoff 3 kDa).  Two milliliters of 1 
mg/mL of the talin F3 domain, 1 mg/mL of wild type FAT domain, and 1 mg/mL talin F3 
+ 1 mg/mL FAT were run over an S75 column (void volume ~ 23 mL) at a flow rate of 
0.3 mL/min.  Fractions containing protein were analyzed by SDS-PAGE.  
NMR of FAT/Talin Interactions 
 The talin F3 domain and wild type 15N-labeled FAT domain were dialyzed into 
NMR buffer (25 mM Tris-Maleate, pH 6.0 or pH 7.5, 150 mM NaCl, and 0.01% NaN3) 
overnight at 4°C.  The proteins were concentrated with an Amicon filtration device (MW 
cutoff 3 kDa (talin), MW cutoff 10 kDa (FAT)), and the concentration was measured 
using the calculated extinction coefficient at 280 nM.  Two samples were made up for 
each pH value.  One sample contained a final concentration of 40 µM 15N-labeled FAT 
domain whereas the other sample contained a final concentration of 40 µM 15N-labeled 
FAT domain and 200 µM unlabeled talin F3 domain to achieve a 5:1 talin:FAT ratio.   
 1H-15N HSQC spectra were collected on a Varian INOVA 500-MHz spectrometer 
equipped with a cold probe at 25°C and 37°C.  The data were processed by NMRPipe 
[85] and visualized with NMRView [86]. 
  
 
CHAPTER 5 
CONCLUSIONS AND FUTURE DIRECTIONS 
Summary 
 Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase that localizes to 
focal adhesions upon integrin activation.  It plays a key role in focal adhesion assembly 
and disassembly and is therefore intimately associated with cell migration and adhesion.  
Overexpression of FAK has been observed in several types of cancer, and increased 
overexpression often correlates with increased metastasis and poor prognosis.  FAK has 
recently become a target for cancer therapeutics.  Therefore, understanding the 
mechanisms by which FAK is regulated could prove vital in designing therapies that 
target specific functions of FAK.  The focus of this study was on the C-terminal focal 
adhesion targeting (FAT) domain of FAK as it plays a key role in FAK function.     
 Various studies have shown that the interaction between the FAT domain and the 
protein paxillin is the major mechanism by which FAK localizes to focal adhesions [34, 
39].  However, secondary paxillin-independent mechanisms for localization have been 
proposed because mutants of FAK that cannot bind to paxillin are still able to localize to 
focal adhesions, albeit at levels about 10% that of wild type FAK [39].  One mechanism 
put forth for paxillin-independent localization is via an interaction between the FAT 
domain and the protein talin.  While several studies have shown an interaction between 
the FAT domain and talin, others have had difficulties detecting this interaction [39], and 
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the existence and possible role for a FAK/talin interactions remains both controversial 
and elusive.     
 The FAT domain of FAK is not only necessary for proper localization of FAK to 
focal adhesions but also plays a key role in proper activation of FAK and signaling 
pathways involved in cell migration and cell proliferation.  In particular, phosphorylation 
of Y926 in the FAT domain has been suggested to promote angiogenesis, cell migration, 
and cell metastasis [19, 47].  Because of its role in these processes, therefore, 
phosphorylation of Y926 may represent an important mechanism by which FAK exerts 
its metastatic effect.  Several studies have addressed the role of phosphorylation of Y926 
by mutating the tyrosine to a nonphosphorylatable residue, namely phenylalanine.  While 
this is a common approach to investigate the role of phosphorylation, mutation could 
affect other processes in addition to preventing phosphorylation.  For example, it has 
been shown that mutating Y926 to a phenylalanine disrupts paxillin binding both in vitro 
and in vivo [47].  Because paxillin binding is the major mechanism by which FAK 
localizes to focal adhesions and paxillin is a substrate of FAK, disruption of paxillin 
binding could affect FAK localization, activation, and signaling.  Because of its proposed 
role in cell migration and metastasis, understanding how phosphorylation of Y926 is 
regulated and how phosphorylation affects the structure of the FAT domain will increase 
our understanding of FAK’s role in cancer.  Furthermore, because of the complications 
with the Y926F mutant, new tools are needed to assess the role of phosphorylation of 
Y926 in vivo.   
 In this study, we conducted a series of biochemical and biophysical experiments 
to better understand regulation of the FAT domain at the molecular level.  In particular, 
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we investigated phosphorylation of Y926, paxillin binding to FAT mutants, and talin 
binding.  We have addressed the following specific topics: 
1. The effect of pH on the structure, dynamics, and phosphorylation of the FAT 
domain. 
2. The effect of mutation of Y926 on the structural features and paxillin binding 
of the FAT domain. 
3. A possible interaction between the FAT domain and the F3 domain of talin. 
The Effect of pH on the FAT domain 
 Summary of Results 
a. The FAT domain is phosphorylated by Src at two sites in vitro, Y926 and 
Y1008. 
b. Phosphorylation at Y926 and Y1008 is pH dependent, with the two sites 
showing a different pH-dependent profile.  In particular, the optimum pH for 
phosphorylation at Y926 is 6.0 whereas the optimum pH for phosphorylation 
at Y1008 is 6.5. 
c. Phosphorylation of linear peptides that contain Y926 and Y1008 suggest that 
it is the structure of the FAT domain and not Src specificity that is dependent 
on pH. 
d. Analysis by CD reveals that the stability of the FAT domain is sensitive to 
pH. 
e. NMR studies suggest that pH affects the dynamics, but not the structure, of 
the FAT domain. 
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 Implications 
 The results described in Chapter 2 are the first evidence that Y1008 is a substrate 
of Src.  While phosphorylation of Y1008 has been observed before [74], it was not 
identified as a Src substrate.  Furthermore, the results suggest that phosphorylation of 
Y926 and Y1008 is differentially regulated by pH.  Under our conditions in vitro, 
optimum phosphorylation of Y926 occurs at pH 6.0 whereas optimum phosphorylation of 
Y1008 occurs at pH 6.5.  These data suggest that pH affects the accessibility of Y926 and 
Y1008 to Src.  Our NMR data suggest that pH affects the dynamics, and not the structure, 
of the FAT domain, which may affect phosphorylation of Y926 and Y1008 although we 
have not been able to fully characterize the pH-dependent dynamics.   
 Previous evidence has shown that because Y926 is in a helical conformation, it is 
not inherently conducive to recognition by Src, and a conformational change must occur 
in order for phosphorylation to occur [48, 49]; however, what causes this conformational 
change has yet to be determined.  Y1008, on the other hand, is in a more unstructured 
region of the FAT domain.  In some structures, Y1008 is in the beginning of helix-4 
whereas in others it is at the end of the loop between helices-3 and -4.  Our data suggest 
that changes in pH may represent one mechanism by which phosphorylation of Y926 is 
regulated.  While the data also suggest that phosphorylation of Y1008 may be regulated 
by pH, further experiments are needed to determine whether phosphorylation of Y1008 
occurs in vivo. 
 It remains to be determined whether the FAT domain of FAK is regulated by pH 
in vivo; however, our results are consistent with recent data that demonstrated a pH 
gradient in migrating cells (from 0.05 to 0.16 pH units depending on cell type) [63].  The 
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leading edge of migrating cells is slightly basic due to the ion-exchange activity of the 
sodium/proton exchanger NHE1.  According to our data, phosphorylation of Y926 is 
prohibited under basic conditions, and indeed, we observe the lowest levels of Y926 
phosphorylation at pH 7.5.  Therefore, one might speculate that at the leading edge of 
cells, Y926 is less likely to be phosphorylated.  The intracellular pH becomes more acidic 
towards the trailing edge of the cell, and according to our data, phosphorylation at Y926 
increases as the pH is decreased from pH 7.5 to pH 7.0.  Therefore, one might speculate 
that Y926 becomes phosphorylated at the trailing edge of cells due to the difference in 
pH between the leading and trailing edges.  This hypothesis is consistent with data that 
demonstrate that Y926 delocalizes FAK from focal adhesions and promotes focal 
adhesion turnover [73].  In summary, our data support a model in which 
nonphosphorylated FAK localizes to focal adhesions at the leading edge of migrating 
cells where the pH is more basic than the overall intracellular pH.  As the cell migrates, 
the leading edge becomes the trailing edge, and the pH becomes more acidic.  These 
conditions promote phosphorylation of Y926 in the FAT domain, which causes 
delocalization of FAK from focal adhesions, focal adhesion turnover, and subsequently 
cell migration.   
 Future Directions 
 In this study, we demonstrated that pH affects the dynamics of the FAT domain; 
however, these dynamics have not been fully characterized.  Attempts to characterize the 
pH-dependent dynamics by CPMG-based relaxation dispersion and hydrogen exchange 
methods were unsuccessful.  It will be of interest to determine whether the pH-dependent 
dynamics can be characterized via other NMR techniques such as T1 rho-based 
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experiments or zz exchange-based experiments, which can provide information on 
dynamics in the ms-sec timescale.  In addition, all of the experiments performed so far 
have investigated the backbone dynamics.  It may be of use to investigate side chain 
dynamics as well. 
 Determining the titrating residue that is causing these pH-dependent changes in 
dynamics will provide a better picture of the pH-dependent dynamics in the FAT domain.  
We have individually mutated the three histidine residues, two aspartate residues, and one 
glutamate residue in the FAT domain and were not able to abrogate the pH-dependent 
stability.  Further experiments would mutate the other aspartate and glutamate residues in 
the FAT domain and/or monitor the carboxyl carbon of aspartate and glutamate residues 
as a function of pH by NMR to determine if these residues are titrating within the pH 5.5 
– 7.5 range.   
 If it is discovered that titration of a particular residue is responsible for the 
observed pH-dependent dynamics, the next step would be to confirm that mutation of this 
residue also alters the pH-dependent phosphorylation of the FAT domain in vitro.  
Finally, if the pH dependence of phosphorylation is altered upon mutation of the titrating 
residue, this mutant would be a good tool to verify whether pH regulates phosphorylation 
of Y926 in vivo. 
 On a separate note, we have shown that Y1008 is a substrate for Src in vitro.  
Future work should determine whether this site is phosphorylated in vivo or whether it is 
simply a product of our in vitro conditions.  If Y1008 is phosphorylated in vivo, it will be 
of great interest to investigate a possible biological function of phosphorylation of 
Y1008.  One possibility for this function could involve talin binding.  As mentioned in 
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Chapter 4, there is preliminary evidence that the F2/F3 domain of talin binds to the FAT 
domain.  While we were unable to detect an interaction between the F3 domain and the 
FAT domain, it is possible that the F2 domain is necessary for the interaction.  Data from 
the laboratory of Dr. David Schleapfer has localized the talin binding site on the FAT 
domain to a region that encompasses Y1008.  Therefore, it would be interesting to 
determine whether phosphorylation of Y1008 affects talin binding. 
 Finally, the original goal of this project was to determine how phosphorylation at 
Y926 affects the structure, dynamics, and ligand binding properties of the FAT domain.  
However, because we were unable to generate a singly phosphorylated species at Y926, 
we were unable to investigate the effect of phosphorylation at Y926.  One way to 
circumvent this issue would be to mutate Y1008.  We have been hesitant about mutating 
Y1008 because we did not want the mutation to affect the structural or functional 
properties of the FAT domain, and we wanted to wait until we had data on the relative 
levels of phosphorylation at Y1008 versus Y926.  However, since it now appears that we 
are unable to preferentially phosphorylate Y926 in vitro, mutation of Y1008 is probably 
the only means to investigate the role of phosphorylation of Y926.  Any Y1008 mutant 
would have to be characterized in vitro to ensure that the mutation does not change the 
structure, stability or paxillin binding of the FAT domain.  Once an appropriate Y1008 
mutant is found, it should be fairly straightforward to phosphorylate the FAT domain in 
vitro.  Previous work by Dr. Kirk Prutzman in the Campbell lab has demonstrated that we 
can purify the phosphorylated form of the FAT domain from the nonphosphorylated form 
by ion exchange chromatography.  Therefore, it should be relatively straightforward to 
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purify a Y926-phosphorylated species, which can be characterized by CD, NMR, and 
paxillin binding. 
Characterization of Y926 Mutants 
 Summary 
1. We created several nonphosphorylatable (Y926F, Y926A, Y926N) and 
phosphomimetic (Y926E, Y926D) mutants.  
2. Analysis by CD reveals that Y926F and Y926A show similar stability and 
similar pH sensitivity to wild type FAT.  The Y926N mutant is less stable 
than wild type but shows similar pH sensitivity.  The Y926D and Y926E 
mutants are also less stable than wild type and are less sensitive to pH. 
3. The 1H-15N HSQC spectra of these mutants show considerable changes in 
chemical shift compared to wild type.  Therefore, further NMR experiments 
are required to assess any structural change in the FAT domain upon mutation 
of Y926. 
4. All the Y926 mutants show decreases paxillin binding compared to wild type, 
with the Y926F mutant being most similar to wild type. 
 Implications 
 The results described in Chapter 3 demonstrate that mutation of Y926 in the FAT 
domain disrupts paxillin binding.  These results are consistent with those of Kaneda et al., 
which showed that the Y926F mutant was deficient in paxillin binding [47].  However, 
these are the first results to show that introducing a negative charge at Y926 via mutation 
to a glutamate or aspartate virtually eliminates paxillin binding.  These results suggest 
that phosphorylation at Y926 may have similar consequences, and while it has been 
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suggested that phosphorylation at Y926 is incompatible with paxillin binding, it has not 
been demonstrated. 
 Furthermore, the fact that every mutation at Y926 that we have tested disrupts 
paxillin binding suggests that Y926 may play an important role in recognizing paxillin.  
The current structural data on a possible interaction between Y926 and paxillin is lacking 
because structures have only been solved with paxillin peptides.  Again, if Y926 is 
essential for recognition of paxillin by the FAT domain, either via hydrophobic or 
hydrogen bonding interactions, perturbation at this site via phosphorylation would be 
expected to disrupt paxillin binding, which would not only affect FAK localization but 
also FAK signaling as paxillin is a substrate of FAK and phosphorylation at Y926 creates 
a binding site for the SH2 domain of Grb2. 
 Finally, we have observed by CD that the stabilities of the Y926E and Y926D 
mutants are less sensitive to pH than wild type.  As described in Chapter 2, we have put 
forth a model in which phosphorylation of the FAT domain may be regulated by pH in 
vivo.  While this model remains to be tested, if the FAT domain is regulated by pH in 
vivo, our results with the Y926E and Y926D mutants suggest that phosphorylation may 
alter the way pH affects the FAT domain and may decrease the sensitivity of the FAT 
domain to pH.  Therefore, according to our model, the FAT domain is phosphorylated at 
the trailing edge of the cell where the pH is more acidic than the leading edge.  Once 
phosphorylated, FAK delocalizes from focal adhesions and participates in MAPK 
signaling via its interaction with Grb2 and pH no longer plays a role in regulation of the 
phosphorylated FAT domain. 
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 Future Directions 
 Our data suggest that Y926 plays a key role in paxillin binding and that any 
perturbation at this site would disrupt paxillin binding.  Further studies need to be done to 
validate this hypothesis.  First, our fluorescence polarization binding studies with the 
FAT domain were conducted with a short peptide designed to mimic the LD2 motif of 
paxillin.  As explained in Chapter 3, the N-terminus of this peptide is near Y926 in the 
FAT domain.  Therefore, these experiments may not be sensitive to interactions between 
Y926 and paxillin.  One solution is to repeat these experiments with a longer paxillin 
construct.  We would probably only need to extend the paxillin peptide by five or six 
amino acids to capture the interaction between Y926 and paxillin.  Fluorescence 
polarization may not be the best experiment to test the longer paxillin construct as our 
dynamic range with the experiment is already on the low side, and increasing the size of 
the peptide will further limit the dynamic range.  ITC would be more suited for these 
experiments as the size of the peptide would not affect the dynamic range of the signal.  
Furthermore, ITC has several advantages over fluorescence polarization in that it 
provides information on stoichiometry and energetics of binding in addition to affinity.  
Since we know that the LD2 peptide binds to two sites on the FAT domain [43] and 
Y926 is expected to effect one the sites but not the other, information regarding the 
stoichiometry of binding would be useful in interpreting the change in paxillin binding 
observed upon mutation of Y926. 
 Further characterizing the structure of the Y926 mutants by NMR will also help 
us interpret the change in paxillin binding of these mutants.  To accomplish this, we must 
first assign the 1H-15N HSQC spectra of the mutants by collecting a 3D HNCACB dataset 
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for each mutant.  Once that is accomplished, we can assess structural changes in the 
Y926 mutants by collecting NH RDCs and Hα-Cα RDCs.  If any of these mutations 
appear to be causing a structural change, we may acquire further structural data such as 
NOEs.  In particular, the Y926E mutant may be of interest as it may mimic the effects of 
phosphorylation; also, the Y926F mutant may also be of interest as it has been used in 
several studies in vivo to assess the role of phosphorylation. 
 Finally, to assess the role of Y926 in paxillin binding, we could model the 
interaction between the LD2 peptide of paxillin and the FAT domain in silico.  This 
process would consist of starting from one of the solved structures of the LD2 peptide 
and the FAT domain, extending the paxillin peptide in silico, assessing the interaction 
between Y926 and LD2, and mutating Y926 to phenylalanine, aspartate, glutamate, 
alanine, and asparagine to determine how mutation might affect specific interactions 
between the FAT domain and paxillin.  Furthermore, it may be possible to model in a 
phosphorylated tyrosine at Y926 to assess how phosphorylation might change specific 
interactions between the FAT domain and paxillin and to help us determine whether 
mutation to aspartate or glutamate would mimic the effects of phosphorylation.  These 
studies would shine new light on the role of Y926 in paxillin binding and hopefully 
provide perspective on how phosphorylation of Y926 might affect paxillin binding.   
FAT/Talin Interactions 
 Summary 
1. We were unable to detect an interaction between the FAT domain and the F3 
domain of talin in vitro by either gel filtration or NMR. 
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 Implications 
 The possibility of an interaction between the FAT domain of FAK and talin has 
been a controversial issue with some groups detecting an interaction [41, 42] and other 
groups unable to detect an interaction [39].  There are several explanations for this 
discrepancy.  First, the interaction between talin and the FAT domain may be indirect.  
While attempts were made to distinguish between a direct and indirect interaction, and 
the data suggested a direct interaction [41], no binding studies have been conducted with 
purified components.  Second, post-translational modifications may be necessary for the 
interaction between the FAT domain and talin.  We would not expect phosphorylation of 
Y926 to promote talin binding as talin binding is associated with focal adhesion 
localization and phosphorylation of Y926 is associated with delocalization.  However, 
there may be other sites of post-translational modification on either the FAT domain or 
talin that promote binding between these two proteins.  One possibility is 
phosphorylation of Y1008 in the FAT domain, which we described in Chapter 2.  Data 
from the Schlaepfer laboratory has localized the talin binding site on the FAT domain to 
a region encompassing Y1008 (personal communication).  Therefore, it will be 
interesting to see how phosphorylation at Y1008 might affect talin binding, if at all. 
 Future Directions   
 We were unable to detect an interaction between the FAT domain of FAK and the 
F3 domain of talin in vitro via gel filtration and NMR.  While the F3 domain of talin is 
the minimal domain necessary for binding to the FAT domain (Dr. David Schlaepfer, 
personal communication), most of the binding assays were performed with a construct 
containing the F2 and F3 domains of talin.  While we have had trouble finding an F2/F3 
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construct of talin that remained soluble at ~100 µM upon addition of the FAT domain, 
other groups have had success crystallizing an F2/F3 domain construct [94], which they 
were able to concentrate to 250 µM.  Therefore, future studies should attempt to purify 
the F2/F3 domain describe in Anthis el al. [94] and repeat the gel filtration and NMR 
experiments described in Chapter 4. 
 If we are able to detect an interaction between the FAT domain of FAK and the 
F2/F3 domain of talin, then a whole world of possibilities is opened up.  First, we would 
want to characterize the binding by either pull-down experiments, ITC, SPR.  We would 
also attempt to structurally characterize the complex by NMR.  If we could gain 
structural information on the complex, we could potentially design mutants in FAK that 
would disrupt talin binding to be used in cells to assess the role of talin binding.  
Furthermore, the structure between the FAT domain and talin would provide information 
on whether phosphorylation of Y1008 would be expected to disrupt, or perhaps promote, 
this interaction, which could support the notion that phosphorylation of Y1008 is relevant 
in vivo. 
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